Daniel W., Nebert Daniel W. Nebert
Professor Emeritus
 
503-694-8482
 
Pub Med Articles  

  Google Scholar

 
View Full CV

Education

Wesleyan University, Middletown, Connecticut B.A. 1956-59
University of Oregon Medical School, Portland M.S. (Biochemistry)
University of Oregon Medical School, Portland M.D. 1959-64
 

Awards

1952
Valedictorian, Garden Home Elementary School 8th Grade, Garden Home, Oregon

1955
Third Place in Humorous Declamation, Oregon State Speech Tournament, Linfield College, Newberg, Oregon

Beaverton High School Medalist at the Oregon State High School Golf Tournament, Glendoveer Golf and Country Club, Portland, Oregon

Selected as high school representative to Beaver Boys’ State, a 2-week course in “Sociology, Geopolitics and Government,” Oregon State University Campus, Corvallis, Oregon

1956
(High School) Future Scientists of America, National First Prize, Biology Section

1956–59
General Motors, Scholarship Scholastic Achievement Award, to attend Wesleyan University, CT

1961
Lawrence Selling Scholarship for Promise in Medical Research

1962
Student American Medical Association Scientific Paper, National Regional Award

1963
Elected first president, Western States Medical Student Research Society, University of Oregon Chapter

Lawrence Selling Scholarship for Promise in Medical Research

1964
Class D Finals, Western Open, U.S. Squash Racquets Association Tournament, Portland, Oregon

1965
Played on same basketball court with Lew Alcindor, Keith Wilkes and Lynn Shackleford (UCLA freshman, who went on to become NBA All-Stars)

1967
Invited Keynote Speaker, Symposium on Biomedical and Biological Applications of Electron Spin Resonance, School of Applied Biology, Georgia Institute of Technology, Atlanta, Georgia

1968
Invited Speaker and Participant, First International Symposium on Microsomes and Drug Oxidations, Bethesda, Maryland

1969-76
Participant in founding a Free Medical Clinic, organized by the Southeast Neighborhood Action Board and Medical Committee for Human Rights, Washington, D.C.––in operation through 1975; it started with a core of one dozen NIH physicians and expanded at its height to 85 NIH physicians practicing pediatrics and adult medicine five evenings per week, for free

Selected Finalist for John D. Lane Award Competition, Fourth Joint Meeting of the Clinical Society and Commissioned Officers' Association of the U.S. Public Health Service, Boston, Massachusetts

1973
Invited Chairman of Discussion Group, “Metabolic Activation as A Factor in Carcinogenic Response,” Conference on Carcinogenesis Testing in the Development of New Drugs, National Academy of Sciences, Washington, D.C.

Co-chairman for organization of workshop, Speaker and Participant, Workshop on Biochemical Genetics, Bar Harbor, Maine

1974
Invited Co-Chairman, Speaker, and Participant, International Symposium on Perinatal Pharmacology, Instituto de Ricerche Farmacologiche “Mario Negri,” Milan, Italy

1975
Elected to membership in the American Society of Clinical Investigation (“Young Turks”) in recognition of outstanding contributions as a Physician-Scientist

Elected to Executive Committee of the Drug Metabolism Division, American Society for Pharmacology and Experimental Therapeutics, Federation of the American Societies for Experimental Biology (3-year term)

Invited Honorary Speaker, Sigma Xi Chapter, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania

1976
Coauthor of paper presented by Steven A. Atlas, Finalist for John D. Lane Award Competition, Eleventh Annual Meeting of the Professional Association of the U.S. Public Health Service, New Orleans, Louisiana

1977
Invited Keynote Speaker, “Frontiers in Biological Sciences,” Case Western Reserve School of Medicine, Cleveland, Ohio

Invited Advisor to the National Institute of Environmental Health Sciences as Member of the United States Environmental Panel, United States-Japan Cooperative Medical Science Program (3-year term)

1978
Recipient of the U.S. Public Health Service Meritorious Service Medal, “In recognition of the special credit and distinction brought to the National Institutes of Health: For his contributions of major importance to contemporary pharmacology and cancer biology in the areas of biochemical genetics and the regulatory process of drug metabolism,” Washington, D.C.

Invited Honorary Speaker, The Annual Pfizer Lecture, The University of Vermont, College of Medicine, Burlington, Vermont

Invited Keynote Speaker, American Pharmaceutical Association, New York, New York

1979
Invited Panel Member, Committee on Chemical Environmental Mutagens, Assembly of Life Sciences, Board on Toxicology and Environmental Health Hazards, National Research Council of the National Academy of Sciences, Washington, D.C. Two-year project, 1979-1981

Selected Recipient by the Japanese Society for the Promotion of Science (JSPS), for 6 weeks of travel and lectures and visitations to more than 20 laboratories throughout Japan

Invited Honorary Speaker, The Annual Pfizer Lecture, Stanford University Medical Center, Stanford, California

1980
Invited Speaker, Participant, and Honored Speaker of Closing Remarks, Third International Congress on the “Biochem-

istry, Biophysics, and Regulation of Cytochrome P-450,” Saltsjöbaden, Sweden

Invited Participant, Conference on “Implications of Environmental/Genetic Interactions,” sponsored by the Institute of

Medicine of the National Academy of Sciences, Washington, D.C.

1981
Bronze Medal Winner, NASTAR Olympics downhill slalom ski racing, Keystone, Colorado

Listed among “The 1,000 Contemporary Scientists Most-Cited 1965-1978,” from a compilation of more than 1 million names in all scientific fields. By Eugene Garfield, Institute for Scientific Information (ISI). [Current Contents, No. 41, 12 October 1981]

1982
Invited Chairman and Participant, The Society for Pediatric Research Annual Meeting, Washington, D.C. Session on Developmental Pharmacology

1983
Invited Symposium Speaker and Participant, Cetus-UCLA Symposium on “Gene Expression,” Park City, Utah

Invited Speaker, Participant, and Co-Organizer, International Symposium on “Extrahepatic Drug Metabolism and Chemical Carcinogenesis,” Stockholm, Sweden

Co-Chairman, Speaker, and Participant, Human Genetics Workshop, Sponsored by the United States-Peoples Republic of China Cooperative Medical Health Protocol, Peking, China. Co-Editor of the book derived from this Workshop

1984
Recognized by the Institute for Scientific Information (ISI) as first author of a Citation Classic(R): Nebert and Gelboin, Journal of Biological Chemistry 243: 6242-6249 (1968). Citation Classic published in the 30 Jan 1984 issue of Current Contents.

Invited Symposium Speaker and Participant, UCLA Symposium on “Molecular Biology of Development,” Steamboat Springs, Colorado

Winner of the Frank Ayrey Fellow Award, among the most prestigious prizes in clinical pharmacology in the United Kingdom

1985
Chairman of the Organizing Committee, Speaker, and Participant, Workshop on “P-450 Genes and Their Regulation,” Airlie, Virginia

Distinguished Lecturer Awardee, Distinguished Lecturer Series in the Life Sciences, Oak Ridge National Laboratory, Oak Ridge, Tennessee

1986
Winner of the Bernard B. Brodie Award on Drug Metabolism, among the most coveted basic-science prizes of the American Society for Pharmacology and Experimental Therapeutics

Invited Symposium Speaker and Participant, The 51st Symposium on Quantitative Biology, “Molecular Biology of Homo sapiens,” Cold Spring Harbor, New York

1987
Chairman of the Organizing Committee, Speaker, and Participant, Second International Workshop on “P450 Gene Regulation,” Airlie, Virginia

Invited Speaker and Participant, Fourth International Symposium on “Oxidases and Related Redox Systems (ISOX IV).” Portland, Oregon

1988
Honored Recipient of the Ernst A. Sommer Memorial Award, Eightieth Lecture Series, Presented in Coordination with the Centennial Celebration of the Oregon Health Sciences University, Portland

Invited Lecturer, Postgraduate Medical Course sponsored by the American Association for the Study of Liver Diseases (AASLD), Chicago, Illinois

1989 Invited Speaker, Symposium on “Molecular Aspects of Liver Metabolism and Disease,” Annual Meeting of the British Association for the Study of the Liver (BASL), London

Chairman of the Organizing Committee, Speaker and Participant, International Workshop on “Genetic Response to Environmental Adversity,” Airlie, Virginia

Invited Speaker and Participant, The Biochemical Society Colloquium on “P450 Gene Regulation, Function and Evolution,” Guildford, United Kingdom

Invited Speaker, International Symposium on Biological Oxidation Systems, Indian Institute of Sciences, Bangalore, India

1990
Keynote Speaker, 26th Annual Meeting of the Norwegian Biochemical Society, Störefjell, Norway

Keynote Speaker, Symposium on Biological Responses to Environmental Adversity, Sixth Annual Meeting of the Cincinnati Section of The American Chemical Society Joint with Sigma Xi, Cincinnati, Ohio

Invited Keynote Speaker to celebrate expansion of a Toxicology Program into a Faculty, Texas A & M University, College Station, Texas

Invited Speaker and Participant, 12th European Workshop on Drug Metabolism, Sponsored by the European Society of Biochemical Pharmacology, Basel, Switzerland

1991
Selected as a Wellcome Visiting Professor in the Basic Medical Sciences, Burroughs Wellcome Fund and the Federation of American Societies for Experimental Biology, Biochemistry and Molecular Biology Division; to visit the University of South Dakota School of Medicine, Vermillion and Sioux Falls, South Dakota

Invited Speaker and Session Chairman, Gordon Conference on Genetic Toxicology, Colby-Sawyer College North, New London, New Hampshire

Invited Speaker, Colloquium on Genome Organization and Evolution, Fifteenth International Congress of Biochemistry, Jerusalem, Israel

Co-Founder of the new journal, Pharmacogenetics, published originally by Chapman & Hall, London. The journal had been in planning stages since 1985

Invited Speaker, Symposium on “Ecogenetics/Pharmacogenetics,” 8th International Congress of Human Genetics, Washington, D.C.

1992
Invited Speaker, Symposium on “Molecular Responses to Environmental Modification of Critical Genes”; Invited Speaker, Symposium on “Ecogenetics: Genetic Susceptibility to Environmental Agents,” 32nd Annual Meeting of the Society of Toxicology, Seattle, Washington

Invited Speaker, Symposium on “Molecular Mechanisms in Carcinogenesis,” Annual Meeting of the American Association for Cancer Research, San Diego, California

Invited Plenary Lecturer, First Annual Reproductive & Developmental Toxicology MiniSymposium, Mount Desert Island Biological Laboratory, Salsbury Cove, Maine

Invited Plenary Lecturer, 8th Colloque International de Biologie Prospective - Eurobiologie 92, and Participant in Town Meeting Debate on “Clinical Chemistry and the Environment,” Metz/Nancy, France

Keynote Speaker, 1992 Midwest Cytochromes P450 Symposium, Purdue University, West Lafayette, Indiana

1993
Invited Speaker, National Advisory Environmental Health Sciences Council (NAEHSC), Session on “Human Gene Markers and the Environment,” Research Triangle Park, North Carolina

Recognized for the second time by the Institute for Scientific Information (ISI) as first author of a Citation Classic(R): Nebert et al., DNA Cell Biology 6: 1-11 (1987). Citation Classic published in the 31 May 1993 issue of Current Contents.

Invited Speaker, National Academy of Sciences Institute of Medicine Conference on Fetal Research and Applications, Irvine, California

Invited Speaker, Joint Meeting of the Medical Research Council Toxicology Unit, University of Leicester, and the British Toxicology Society, Leicester, United Kingdom

Invited Speaker, 6th International Biochemical Pharmacology Symposium on “New Targets for Long-Acting Drugs Involving Translocation to the Nucleus,” Oxford, England

Elected to the Society of Fellows of the Graduate (F.O.G.) School, University of Cincinnati

Invited Speaker, 86th Nobel Symposium “Toward a Molecular Basis of Alcohol Use and Abuse,” Karolinska Institute, Stockholm, Sweden

Honored for his career achievements in genetics and cancer studies, by having his photograph appear on the cover of the 15 Dec 1993 issue of Cancer Research.

1994
Invited co-Chairman, Session Organizer and Speaker, Symposium on “Signal Transduction and Drug Metabolism,” 7th

Annual Meeting of the International Union of Pharmacology (IUPHAR), Montreal, Canada

Invited Speaker and Participant, Symposium on “Pharmacogenetics and Metabolism,” 2nd International Latinoamerican Genetics Congress, Puerto Vallarta, Mexico

Elected to the rank of American Association for the Advancement of Science (AAAS) Fellow, to be awarded at the AAAS Fellows Forum, Annual Meeting of the AAAS, February, 1995, in Atlanta, Georgia

1995
Invited Speaker, Symposium on Molecular Toxicology, Keystone Symposia on Molecular & Cellular Biology, Copper Mountain, Colorado

Invited Speaker, Symposium on “Mechanistic Basis of Ethnic Differences in Cancer Risk,” and Invited Speaker, Symposium on “Contribution of Environmental Factors to Cancer,” American Association for Cancer Research, Toronto, Ontario, Canada

Invited Plenary Speaker, International Congress on “Hazardous Waste: Impact on Human and Ecological Health,” Atlanta, Georgia

Invited Speaker, Symposium on “Gene Families: Structure, Function, Genetics and Evolution,” 8th International Congress on Isozymes, Brisbane, Australia

1996
Invited Speaker, Symposium on “Genes Encoding Drug-Metabolizing Enzymes during Reproduction and Development,” 36th Annual Meeting of the Society of Toxicology, Anaheim, California

Keynote Speaker, “Visions in Pharmacology” Research Day, University of Toronto Medical Center, Toronto, Ontario Invited Plenary Lecturer, 36th Annual Meeting of the Teratology Society, Keystone, Colorado

Invited Chairman, Session Organizer and Speaker, Workshop on “Pharmacogenetics at the Molecular Level,” 9th International Congress of Human Genetics, Rio de Janeiro, Brazil

Invited Speaker, Barrett Cancer Conference on “Controversies and Emerging Issues in Lung Cancer,” Cincinnati, Ohio

1997
Invited Participant, “Translating Advances in Genetics into Public Health Action,” sponsored by the Genetic Epidemiology Task Force of the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia

Invited Speaker, Symposium on “Perturbation of the Mitosis/Apoptosis Balance: A Fundamental Mechanism in Toxicology,” 37th Annual Meeting of the Society of Toxicology, Cincinnati, Ohio

Invited Speaker, Symposium on “Genetic Determinants of Susceptibility to Toxic Agents,” 37th Annual Meeting of the Society of Toxicology, Cincinnati, Ohio

Invited Keynote Speaker and Participant, First Annual Workshop on “Transgenic Model Systems and Molecular Toxicology,” National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, North Carolina

Invited Speaker, Second International Meeting on “Redox Processes and Cancer,” Banff, Alberta, Canada

Invited Speaker and Participant, International Nomenclature Workshop, sponsored by the International Committee on Standardized Nomenclature in Mice and the HUGO Human Gene Nomenclature Committee, Bar Harbor, Maine

Invited Speaker and Participant, Satellite Symposium “Microsomes, Drug Oxidation and Clinical Pharma-cology,” in conjunction with the 2nd Congress of the European Association for Clinical Pharmacology and Therapeutics, Berlin, Germany

Invited Honorary Guest Speaker and Participant, International Dioxin Symposium, Seoul, South Korea

1998
Invited Speaker and Participant, Symposium on “Actions of Natural and Synthetic Xenobiotics on Nuclear Receptors,” Annual Meeting of the German Society of Pharmacology and Toxicology, Mainz, Germany

Invited Speaker, 2nd Annual Workshop on “Transgenic Model Systems & Molecular Toxicology,” National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, North Carolina

Recipient of the 1998 University of Cincinnati Distinguished Research Professorship Award, “highest honor this university can give in recognition of excellence in research, a most prestigious honor that is bestowed usually only once every 1 to 3 years”

Invited Speaker and Participant, Session on “Transgenic animals to predict drug metabolism,” 12th International Symposium on Microsomes and Drug Oxidations, Montpellier, France

Invited Speaker and Participant, Workshop on “Rodent Models in Modern Risk Assessment,” The Jackson Laboratory, Bar Harbor, Maine

Invited Speaker and Participant, Session on “Stress response mechanisms,” 5th International Meeting of the International Society for the Study of Xenobiotics (ISSX), Cairns, Australia

Invited Speaker and Participant, Workshop on “Genetic Susceptibility to Environmental Exposure,” Institute for Science, Law, and Technology, Illinois Institute of Technology, Chicago

Invited Speaker, Participant, and Member of the Conference Organizing Committee, 12th Annual International Barton Creek Conference on Carcinogenesis and Risk Assessment, “Gene-Environment Interactions: Emerging Issues, Technologies and Biological Paradigms,” Barton Creek, Texas

1999
Invited Speaker and Participant, National Institutes of Health/U.S. Food and Drug Administration (NIH/FDA) Conference on “Biomarkers and Surrogate Endpoints: Clinical Research and Applications,” Toxicology Biomarkers Breakout Session, Bethesda, Maryland

Invited Speaker and Participant, Second International Nomenclature Workshop (INW2), Cambridge, United Kingdom

Recipient of the 1999 University of Cincinnati George Rieveschl Jr Award for Distinguished Scientific Research, “in recognition of a lifetime career of highly successful, innovative, and distinguished scientific research in the field of environmental genetics, toxicology, evolution and gene nomenclature”

Invited Speaker and Participant, 7th International Biochemical Pharmacology Symposium, “Redox-Controlled Gene Regulation in Environmental Toxicity and Cancer,” Oxford, United Kingdom

Keynote Speaker and Participant, Annual Meeting of the Japanese Society of Toxicology, Sapporo, Japan

Winner of First Prize, Blue Ribbon, Salad Division, Family Exhibits Section, 109th Annual Tillamook County Fair, Tillamook, Oregon

Invited Speaker and Participant, New York Academy of Sciences Meeting on “Toxicology for the Next Millenium” (Lederberg J, Isfort R, co-Organizers), Airlie, Virginia

Invited Speaker and Participant, Symposium on “Gene-Environment Interactions, Cancer and Toxicity,” 49th Annual Meeting of the American Society of Human Genetics, San Francisco, California

Invited Keynote Speaker and Participant, Symposium on “Genetic Susceptibility to Environmental Toxicants,” Annual Meeting of the Ohio Valley Society of Toxicology (OVSOT), Louisville, Kentucky

Invited Keynote Speaker and Participant, First National Biomedical Symposium on “Panamanian Populations and Its Frontiers,” Panamá City, Republic of Panamá

2000
Invited Speaker and Participant, Session on “Human Susceptibility and Mechanistic Toxicology,” Environmental Protection Agency/Department of Defense (EPA/DOD) Annual Conference on Toxicology, Cincinnati, Ohio

Invited Speaker and Participant, Session on “Drug-Metabolizing Enzymes: Polymorphisms and Individual Response to the Environment,” IFCC-Roche Joint Conference “Human Genomics, the Basis of the Medicine of Tomorrow. Validating and Using Pharmacogenomics,” Kyoto, Japan

Invited Speaker and Participant, Session on “Emerging Biomarker Methodologies,” International Conference on Arctic Development, Pollution and Biomarkers of Human Health (sponsored by the National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, and the Arctic Monitoring and Assessment Program), Anchorage, Alaska

Invited Speaker and Participant, Session on “New Technology in the Field of Drug-Metabolizing Enzymes: Pharmaco- and Toxico-Genomics,” 13th International Symposium on Microsomes and Drug Oxidations, Stresa, Italy

Invited Participant, the Human Gene Nomenclature Workshop and the HUGO Mutation Database Initiative Meeting, satellite meeting of the Annual Meeting of the American Society of Human Genetics, Philadelphia, Pennsylvania

Invited Speaker and Participant, Cambridge Healthtech Institute’s 2nd Annual “Pharmacogenomics: A New Script for Prescriptions” Conference, Philadelphia, Pennsylvania

2001
Invited Speaker, Symposium on “Pharmacogenetics and Drug Metabolism,” at the 41st Annual Meeting of the Society of Toxicology, San Francisco, California

Invited Speaker and Participant, National Institute of Child Health and Human Development/Food and Drug Administration (NICHD/FDA) Workshop on “Adverse Drug Reactions in Pediatrics,” Bethesda, Maryland

Keynote Speaker, Penn State University Life Sciences Consortium’s Colloquium, Pennsylvania State School of Medicine, Hershey, Pennsylvania

Invited Speaker, Symposium on “Transcription Factors and Cancer,” at the 9th International Union of Toxicology (IUTOX) Congress of Toxicology, Brisbane, Australia

Invited Speaker, at the 18th International Symposium on Polycyclic Aromatic Compounds, sponsored by the International Society for Polycyclic Aromatic Compounds (ISPAC), Cincinnati, Ohio

Plenary Lecture on “The Human Genome Project and the future of pharmacogenomics,” Annual Meeting of the Joint Chinese-Australian Colleges of Pathologists, Hong Kong Academy of Medicine, Hong Kong, China

Invited Chair, session on “The Environmental Genome Project,” Symposium on Gene Expression and Proteomics in Environmental Health Research,” sponsored by the National Center for Toxicogenomics (NCT) and the National Institute of Environmental Health Sciences (NIEHS), Bethesda, Maryland

2002
Recognized for the third time by the Institute for Scientific Information (ISI) as coauthor of a Citation Classic(R): Nelson et al., Pharmacogenetics 6: 1-42 (1996). Citation Classic published in ISI’s Essential Science Indicators (ESI) on the website http://www.esi-topics.com

Listed among “The top 0.1% Contemporary Scientists Most-Cited 1981-1999,” from a compilation of more than 5 million names in all scientific fields. By Eugene Garfield (Emeritus), Institute for Scientific Information, Philadelphia, Pennsylvania

Invited Speaker, Symposium on “Genetic susceptibility to inhaled pollutants,” at the 42nd Annual Meeting of the Society of Toxicology, Nashville, Tennessee

Invited Chair, Symposium on “Applying new biotechnologies to the study of occupational cancer,” sponsored by National Institute of Occupational Safety & Health (NIOSH), Washington, D.C.

Invited Speaker, Symposium on “Ethnic and genetic variation in response to occupational chemicals,” Third International Conference on Oxygen/Nitrogen Radicals: Cell Injury and Disease,” sponsored by the National Institute of Occupational Safety & Health (NIOSH), Morgantown, West Virginia

Invited Speaker, Symposium on “Human genetic variability,” 38th Annual Meeting of the Drug Information Association (DIA), Chicago, Illinois

Invited Overview Speaker, Symposium on “Role of Cytochromes P450 in Proliferation, Differentiation, and Apoptosis,” at the 14th International Union of Pharmacology (IUPHAR) Congress of Toxicology, San Francisco, California

Invited Speaker, Session on “Genomics and Bio-Informatics,” 14th International Symposium on Microsomes and Drug Oxidations, Sapporo, Japan

Keynote Speaker, First Scientific Symposium of the Comparative Mouse Genomics Centers Consortium (CMGCC), Seattle, Washington

Keynote Speaker, Plenary Session “Human Genome: the Aftermath and the Future,” 11th Meeting of the North American International Society for the Study of Xenobiotics (ISSX), Orlando, Florida

Invited Speaker, Symposium on “Pharmacogenetics of Drug-Metabolizing Enzymes,” Annual Meeting of the American Association of Pharmaceutical Scientists (AAPS), Toronto, Canada

2003
Invited Speaker, Conference on Molecular and Genetic Epidemiology and Cancer, co-sponsored by the American Association for Cancer Research (AACR) and the Society of Toxicology (SOT), Waikoloa, Hawaii

Invited Speaker, Symposium on Race and Ethnicity in Medical Scientific Research, Annual Meeting of the American Association for the Advancement of Science (AAAS), Denver, Colorado

Plenary Lecture, Session on Human Genomics, International Symposium of the Pacific Rim Association of Clinical Pharmacogenetics, Los Angeles, California

2004
Invited Speaker, Session on Transgenic Mice Used in Drug Metabolism Toxicity, Discovery Strategies 2004, sponsored by The Jackson Laboratory, Bar Harbor, Maine

Honored Speaker, Session on “From Pioneer Times to Latest Advances,” 15th International Symposium on Microsomes and Drug Oxidations [Symposium dedicated to Professors Sten Orrenius & Daniel W Nebert], Mainz, Germany

Invited Keynote Address, “Interindividual responses to environmental toxicants—an overview,” Session on “Polymor- phisms and Gene Regulation: Toxicological Impact,” Tenth International Congress of Toxicology (ICTX), Tampere, Finland

Invited Feature Speaker, 20th Annual Meeting of the Mountain States Regional Genetics Network, sponsored by the American Board of Medical Genetics, Denver, Colorado

Invited Speaker, 3rd Annual Symposium on Pharmacogenomics, Second International “Biologie Perspective” Santorini Conference, Santorini, Greece

2005
Winner of the Society of Toxicology’s Distinguished Lifetime Toxicology Scholar Award, presented at 25th Annual SOT Meeting, New Orleans, Louisiana

Plenary Speaker, European Environmental Mutagenesis Society, Kos, Greece

Invited Speaker, 12th Annual Mount Desert Island Biological Laboratory Environmental Health Sciences Symposium, “Molecular evolution of chemical defense mechanisms,” Bar Harbor, Maine

One of ten lecturers to ~500 incoming Univ Cincinnati honors freshmen for their class: “Five Pillars of Honor: Leadership, Global Studies, Community Engagement, Research & Creative Arts, and Interdisciplinary Studies,” Cincinnati Ohio

2006
Participant in Debate, “ ’Omics are of value in safety evaluation,” 46th Annual Meeting of Society of Toxicology, San Diego, California

Special Lecturer, 126th Annual Meeting of the Japanese Pharmaceutical Society, Tokyo, Japan

Keynote Speaker, 13th Annual Meeting of the Pan-American Society for Pigment Cell Research, Cincinnati, Ohio

Participant in Debate, “ ’Omics are of value in safety evaluation,” 43rd Congress of the European Society of Toxicology, Dubrovnik, Croatia

2007
Invited Speaker, Ohio State University Comprehensive Cancer Center’s 9th Annual Scientific Meeting, Columbus, Ohio

Invited Speaker, Symposium on “Application of Humanized Mouse Lines to Toxicological and Pharmacology Studies,” 47th Annual Meeting of the Society of Toxicology, Charlotte, North Carolina

Invited Speaker, Symposium on “The Vascular System as a Target of Heavy Metal Toxicity,” 47th Annual Meeting of the Society of Toxicology, Charlotte, North Carolina

Recognized by the Institute for Scientific Information (ISI) as “Among the Top Ten Most Cited Authors” in the category of “Pharmacology & Toxicology” for every 10-year-6-month “window” between January 1990 and June 2007, at which time these windows were discontinued by ISI. The other five of the six ISI categories (also used by the Committee for the Nobel Prize in Physiology or Medicine) include “Biology & Biochemistry”, “Immunology”, “Microbiology”, “Molecular Biology & Genetics”, and “Neuroscience & Behavior”; see the website http://www.esi- topics.com

2008
Invited Speaker, Symposium on “How Do Air Pollutants Promote Airway Inflammation and Contribute to Asthma Morbidity?” Annual Meeting of the American Academy of Allergy, Asthma & Immunology, Philadelphia, Pennsylvania

Invited Speaker, Symposium on Pharmacogenetics in Memory of Professor Maria Celeste Lechner, Lisbon, Portugal

Invited Speaker, Gordon Conference on “Toxicant-Risk Factor Interactions in Chronic Disease”, Bates College, Lewiston, Maine

Invited Speaker, Third American Association for Cancer Research (AACR) International Conference on “Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine”, Philadelphia, Pennsylvania

Invited Speaker, Joint American Association Pharmaceutical Scientists-International Pharmaceutical Federation (AAPS- FIP) Workshop on “Pharmacogenetics in Individualized Medicine: Methods, Regulatory and Clinical Applications”, Atlanta, Georgia

2009
Course Director, Symposium on “Darwin, Evolution and Relevance to Clinical Medicine”, Continuing Medical Education (CME) for University Cincinnati Medical School Alumni, Cincinnati, Ohio

Invited Speaker and Chair of Session “Posttranscriptional and posttranslational events”, 16th International Conference on “Cytochrome P450: Biochemistry, Biophysics, Biotechnology”, Nago, Okinawa, Japan

Invited Keynote Lecture, Symposium on “Cyp-knockout and CYP-humanised mouse models”, United Kingdom Environmental Mutagen Society (UKEMS) Annual Meeting, Leeds, United Kingdom

Course Director, Mini-Medical School Series, “Darwin, Evolution, and Clinical Medicine”, given for nurses and undergraduate students, eight lectures, four weeks, October, at Cincinnati, Ohio

Invited Speaker, The Cincinnati Woman’s Club, “Darwin’s 200th birthday, scientific proof of evolution: why we metabolize drugs differently”, Cincinnati, Ohio

2010
Invited Keynote Speaker, Symposium on Drug Metabolism: “Xenobiotics––from evolution to clinical medicine”, University of Oulu, Finland

Invited Keynote Speaker, Annual Helsinki Biomedical Graduate School (HBGS) Student Council Symposium “Frontiers in Personalized Medicine”, at Biomedikum Helsinki and University of Helsinki, Finland

Invited Speaker and Participant, Fujihara Seminar 2010: Zinc signaling and cellular functions, Osaka University, Osaka, Japan

2011
Invited Speaker, Symposium on “Human Variability in Susceptibility to Environmental Toxicants,” 51st Annual Meeting of the Society of Toxicology, Washington, DC

Invited Speaker, The Cincinnati Woman’s Club, “Personalized medicine, individualized drug therapy: will these ever be realized?” Cincinnati, Ohio

2012
Invited Speaker and Participant, "Transporters" Session, Biannual Meeting of the International Society of Zinc Biology, Melbourne, Australia

Invited to participate as Host Mentor for the Minority and Underprivileged Undergraduate Education Program, Society of Toxicology 52nd Annual Meeting, San Francisco, California

Invited to participate in TEDxCincinnati Symposium on "Ideas in Technology, Education and Design", sponsored by Bill & Melinda Gates Foundation; lecture is now uploaded and can be viewed on YouTube; Cincinnati, Ohio

Invited to speak to all Biology classes, Cherry Creek High School ("The 203rd birthday of Charles Darwin and evolution today"), Denver, Colorado

Invited Plenary Speaker, at 17th Annual John Doull Toxicology Symposium, University Kansas Medical Center, Kansas City, Kansas

Director's Award, Department of Environmental Health, University of Cincinnati, for "a lifetime career of outstanding contributions to environmental genetics research"

2013
Invited by Graduate Student Leadership Committee (GSLC) to participate in Chat with an Expert (CWAE) program, meeting with grad students & postdoctoral fellows, 53rd Annual Meeting of the Society of Toxicology, San Antonio, Texas

Honored Plenary Speaker at Center for Environmental Genetics Annual Symposium, University Cincinnati Medical Center and Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Invited Plenary Speaker, Gordon Research Conference, “Cell Biology of Metals”, Salve Regina University, Newport, Rhode Island

2014
Invited to participate as one of six to eight speakers and panelists, Roundtable on "University of Cincinnati bridging the gap: social engagement and public intellectuals", sponsored by the Philosophy Graduate Student Association; "purpose is to analyze the causes of alienation of intellectuals from the rest of society and to brainstorm strategies to facilitate a better interaction between intellectuals, the media, and society"

Invited Speaker and Participant, The 6th Annual Physicians' Round Table, Sponsored by the Short-Order radio show for healthcare professionals, "Accentuating the 'Heal' in Health", Tampa, Florida

2015
Invited Keynote Speaker and Participant, "Current Research on Benzo[a]pyrene", Seoul, South Korea
 

Professional Experience

1964-65 Pediatric Intern, UCLA Center for Health Sciences, Los Angeles

1965-66 Pediatric Resident II, UCLA Center for Health Sciences, Los Angeles

1966-68 Research Associate (postdoctoral fellow), Chemistry Branch, Etiology Area, National Cancer Institute, NIH, Bethesda, Maryland

1968-71 Senior Investigator, Section on Developmental Enzymology, Laboratory of Biomedical Sciences, National Institute of Child Health and Human Development, NIH, Bethesda, Maryland

1971-74 Head, Section on Developmental Pharmacology, Laboratory of Biomedical Sciences, National Institute of Child Health and Human Development, NIH, Bethesda, Maryland

1974-75 Acting Chief, Neonatal and Pediatric Medicine Branch, and Head, Section on Developmental Pharmacology of the Neonatal and Pediatric Medicine Branch, National Institute of Child Health and Human Development, NIH, Bethesda

1975-89 Chief, Laboratory of Developmental Pharmacology, and Head, Section on Pharmacogenetics, National Institute of Child Health and Human Development, NIH, Bethesda, Maryland

1974-82 Attending Clinical Staff (one month each year), Pediatrics Ward, National Institute of Child Health and Human Development, NIH, Bethesda, Maryland

1980-89 Adjunct Professor, Department of Pharmacology, Uniformed Services University of the Health Sciences, School of Medicine, Bethesda, Maryland

1981-89 Member of the NIH-Wide Human Genetics Clinical Training Program Faculty for Board Certification in Human Genetics

1982-89 Designated by the Director of N.I.H. (James Wyngaarden) to be U.S. Coordinator for the Medical Genetics Program, of the United States-People's Republic of China Cooperative Medical Health Protocol

1989-2013 Professor, Department of Environmental Health, University of Cincinnati Medical Center

1991-2013 Professor, Department of Pediatrics and Molecular Developmental Biology, Division of Human Genetics, Children's Hospital Medical Center

1992-97 Founder and Director, Center for Environmental Genetics, funded and approved by the National Institute of Environmental Health Sciences, now includes 45 senior scientists with their own independent research programs from eleven departments in the University of Cincinnati College of Medicine, College of Arts and Sciences, and The Children's Hospital Medical Center

1994-98 Associate Director, Physician Scientist Training Program for M.D./Ph.D, College of Medicine, University of Cincinnati Medical Center

1995-88 Invited to join the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (IUBMB), the International Union of Pure and Applied Chemistry (IUPAC) and the IUPAC-IUBMB Joint Commission on Biochemical Nomenclature (JCBN), stemming from the 1993 meeting in Marseille, to promote the nomenclature of various gene superfamilies on the basis of divergent evolution

1999-2004 Invited to join the National Advisory Environmental Health Sciences Council (NAEHSC), which reviews—three times each year—all National Institute of Environmental Health Sciences (NIEHS) grant applications; Research Triangle Park, North Carolina

1999– Invited to join the 17-member International Advisory Committee (IAC) of the Human Gene Nomenclature Committee (HGNC). Endorsed by the Council of the Human Genome Organization; initially, a 6-year term, now extended indefinitely, London, England

2000– Invited to join the Expert Scientific Council (ESC) of the Protein Information Resource (PIR) of the National Biomedical Research Foundation, based at Georgetown University, Washington DC

2013– Professor Emeritus, Department of Environmental Health, University of Cincinnati Medical Center

2013– Professor Emeritus, Department of Pediatrics & Molecular Developmental Biology, Division of Human Genetics Children's Hospital Medical Center

2013– Adjunct Professor, Department of Environmental & Molecular Toxicology, Oregon State University

Selected Publications

1. Nebert DW, Mason HS, 1963; An electron spin resonance study of neoplasms. Cancer Res 23, 833-840
2. Nebert DW, Mason HS, 1964; A microsomal difference between normal liver and “minimal deviation” hepatoma 5123 detectable by electron spin resonance. Biochim Biophys Acta 86, 415-417
3. Nebert DW, 1964; An electron spin resonance study of normal and neoplastic biological material. (Thesis), University of Oregon Medical School, 117 pp
4. Allen BT, Nebert DW, 1966; Hyperfine structure in the EPR spectrum of the manganous ion in frozen solutions. J Chem Phys 41, 1983-1985
5. Nebert DW, Curtis DD, 1966; Hypoproteinemia and cystic fibrosis. Calif Med 104, 57-59
6. Nebert DW, Allen BT, 1966; Environmental factors influencing the hyperfine structure of manganous low-temperature
electron paramagnetic resonance spectra. Biophys J 6, 189-200
7. Nebert DW, Goldberg SJ, Gaal PG, Burckin AP, 1966, Pyloric stenosis: a case in which a second gastrointestinal lesion was
masked by a gastrostomy. Am J Dis Child 111, 544
8. Nebert DW, Gelboin HV, 1968, Substrate-inducible microsomal aryl hydroxylase in mammalian cell culture: I. Assay and
properties of induced enzyme. J Biol Chem 243, 6242-6249
9. Nebert DW, Gelboin HV, 1968, Substrate-inducible microsomal aryl hydroxylase in mammalian cell culture: II. Cellular
responses during enzyme induction. J Biol Chem 243, 6250-6261
10. Nebert DW, Gelboin HV, 1969, Drugs and microsomal enzyme formation in vitro and in mammalian cell culture. In: Microsomes and Drug Oxidations (Gillette JR, Conney AH, Cosmides GR, Estabrook RW, Fouts JR, Mannering GJ, eds), pp 389-429, Academic Press, New York
11. Gelboin HV, Younger LR, Nebert DW, Miller JM, 1969, In vivo and in vitro studies on the mechanism of microsomal enzyme induction. In: Proc IVth Intern Pharmacol Congress, vol IV, pp 287-306, Schwäbe and Company, Basel/Stuttgart
12. Nebert DW, 1969, Changes in aryl hydrocarbon hydroxylase activity and microsomal P-450 during polycyclic hydrocarbon treatment of mammalian cells in culture. Biochem Biophys Res Commun 36, 885-890
13. Nebert DW, Gelboin HV, 1969, The in vivo and in vitro induction of aryl hydrocarbon hydroxylase in mammalian cells of different species, tissues, strains, and developmental and hormonal states. Arch Biochem Biophys 134, 76-89
14. Nebert DW, Winker J, Gelboin HV, 1969, Aryl hydrocarbon hydroxylase activity in human placenta from cigarette smoking and nonsmoking women. Cancer Res 29, 1763-1769
15. Nebert DW, Gelboin HV, 1970, The role of ribonucleic acid and protein synthesis in microsomal aryl hydrocarbon hydroxylase induction in cell culture: The independence of transcription and translation. J Biol Chem 245, 160-168
16. Nebert DW, 1970, Microsomal cytochrome b5 and P450 during induction of aryl hydrocarbon hydroxylase activity in mammalian cell culture. J Biol Chem 245, 519-527
17. Nebert DW, Bausserman LL, 1970, Fate of inducer during induction of aryl hydrocarbon hydroxylase activity in mammalian cell culture. I. Intracellular entry, binding, distribution and metabolism. Mol Pharmacol 6, 293-303
18. Nebert DW, Bausserman LL, 1970, Fate of inducer during induction of aryl hydrocarbon hydroxylase activity in mammalian cell culture. II. Intracellular content of polycyclic hydrocarbon during enzyme induction and decay. Mol Pharmacol 6, 304- 314
19. Nebert DW, Bausserman LL, Bates RR, 1970, Effect of estradiol and testosterone on aryl hydrocarbon hydroxylase activity in mouse tissue in vivo and in cell culture. Int J Cancer 6, 470-480
20. Nebert DW, Bausserman LL, 1970, Genetic differences in the extent of aryl hydrocarbon hydroxylase induction in mouse
fetal cell cultures. J Biol Chem 245, 6373-6382
21. Friedman RM, Nebert DW, 1971, Viral interference: The mechanism of action of interferon. In: Regulation of Cell Metabolism: Organization and Pharmacological Aspects on the Molecular Level (Mihich E, ed), pp 309-329, Academic Press, New York
22. Nebert DW, Bausserman LL, 1971, Aryl hydrocarbon hydroxylase induction in cell culture as a function of gene expression. Ann N Y Acad Sci 179, 561-579
23. Nebert DW, Goujon FM, Gielen JE, 1971, Genetic regulation of monooxygenase activity. In: Fonds de la Recherche Scientifique Medicale, Groupes de Contact (Heusghem C, ed), pp 240-270, 11 ru d'Egmont, Bruxelles 5, Belgium
24. Gielen JE, Nebert DW, 1971, Microsomal hydroxylase induction in liver cell culture by phenobarbital, polycyclic hydrocarbons, and p,p'-DDT. Science 172, 167-169
25. Gielen JE, Nebert DW, 1971, Aryl hydrocarbon hydroxylase induction in mammalian liver cell culture. I. Stimulation of enzyme activity in nonhepatic cells and in hepatic cells by phenobarbital, polycyclic hydrocarbons, and 2,2-bis(p- chlorophenyl)-l,l,l-trichloroethane. J Biol Chem 246, 5189-5198
26. Nebert DW, Gielen JE, 1971, Aryl hydrocarbon hydroxylase induction in mammalian liver cell culture. II. Effects of actinomycin D and cycloheximide on induction processes by phenobarbital or polycyclic hydrocarbons. J Biol Chem 246, 5199-5206
27. Nebert DW, Gielen JE, 1972, Genetic regulation of aryl hydrocarbon hydroxylase induction in the mouse. Fed Proc 31, 1315-1325
28. Nebert DW, Goujon FM, Gielen JE, 1972, Genetic regulation of aryl hydrocarbon hydroxylase induction in vivo and in cell culture. In: Beiträge zur Entwicklungspharmakologie (Ankermann H, Träger A, eds), pp 185-203, Drückerei “Magnus Poser,” Jena, East Germany
29. Gielen JE, Goujon FM, Nebert DW, 1972, Genetic regulation of aryl hydrocarbon hydroxylase induction. II. Simple Mendelian expression in mouse tissues in vivo. J Biol Chem 247, 1125-1137
30. Nebert DW, Goujon FM, Gielen JE, 1972, Aryl hydrocarbon hydroxylase induction by polycyclic hydrocarbons: Simple autosomal dominant trait in the mouse. Nature New Biol 236, 107-110
31. Benedict WF, Gielen JE, Nebert DW, 1972, Polycyclic hydrocarbon-produced toxicity, transformation, and chromosomal aberrations as a function of aryl hydrocarbon hydroxylase activity. Int J Cancer 9, 435-451
32. Nebert DW, Benedict WF, Gielen JE, Oesch F, Daly JW, 1972, Aryl hydrocarbon hydroxylase, epoxide hydrase, and 7,12- dimethylbenz[a]anthracene-produced skin tumorigenesis in the mouse. Mol Pharmacol 8, 374-379
33. Benedict WF, Paul B, Nebert DW, 1972, Expression of benz[a]anthracene-inducible aryl hydrocarbon hydroxylase activity in mouse-hamster and mouse-human somatic-cell hybrids. Biochem Biophys Res Commun 48, 293-298
34. Benedict WF, Nebert DW, Thompson EB, 1972, Expression of aryl hydrocarbon hydroxylase induction and suppression of tyrosine aminotransferase induction in somatic-cell hybrids. Proc Natl Acad Sci USA 69, 2179-2183
35. Gielen JE, Nebert DW, 1972, Aryl hydrocarbon hydroxylase induction in mammalian liver cell culture. III. Effects of various sera, hormones, biogenic amines, and other endogenous compounds on the enzyme activity. J Biol Chem 247, 7591- 7602
36. Nebert DW, Gielen JE, Goujon FM, 1972, Genetic expression of aryl hydrocarbon hydroxylase induction. III. Changes in the binding of n-octylamine to cytochrome P-450. Mol Pharmacol 8, 651-666
37. Goujon FM, Nebert DW, Gielen JE, 1972, Genetic expression of aryl hydrocarbon hydroxylase induction. IV. Interaction of various compounds with different forms of cytochrome P-450 and the effect on benzo[a]pyrene metabolism in vitro. Mol Pharmacol 8, 667-680
38. Nebert DW, Kon H, 1973, Genetic regulation of aryl hydrocarbon hydroxylase induction. V. Specific changes in the spin
state of cytochrome P450 from genetically responsive animals. J Biol Chem 248, 169-178
39. Poland AP, Nebert DW, 1973, A sensitive radiometric assay for aminopyrine N-demethylation. J Pharmacol Exp Ther 184,
227-269
40. Nebert DW, Friedman RM, 1973, Stimulation of aryl hydrocarbon hydroxylase induction in cell cultures by interferon. J
Virol 11, 193-197
41. Benedict WF, Considine N, Nebert DW, 1973, Genetic differences in aryl hydrocarbon hydroxylase induction and
benzo[a]pyrene-produced tumorigenesis in the mouse. Mol Pharmacol 9, 266-277
42. Nebert DW, Considine N, Owens IS, 1973, Genetic expression of aryl hydrocarbon hydroxylase induction. VI. Control of other aromatic hydrocarbon-inducible monooxygenase activities at or near the same genetic locus. Arch Biochem Biophys 157, 148-159
43. Oesch F, Morris N, Daly JW, Gielen JE, Nebert DW, 1973, Genetic expression of the induction of epoxide hydrase and aryl hydrocarbon hydroxylase activities in the mouse by phenobarbital or 3-methylcholanthrene. Mol Pharmacol 9, 692-696
44. Nebert DW, Considine N, Kon H, 1973, Genetic differences in cytochrome P-450 during induction of monooxygenase activities. Drug Metab Dispos 1, 231-238
45. Nebert DW, 1973, Use of fetal cell culture as an experimental system for predicting drug metabolism in the intact animal. Clin Pharmacol Ther 14, 693-699
46. Benedict WF, Gielen JE, Owens IS, Niwa A, Nebert DW, 1973, Aryl hydrocarbon hydroxylase induction in mammalian liver cell culture. IV. Stimulation of the enzyme activity in established cell lines derived from rat or mouse hepatoma and from normal rat liver. Biochem Pharmacol 22, 2766-2769
47. Nebert DW, Heidema JK, Strobel HW, Coon MJ, 1973, Genetic expression of aryl hydrocarbon hydroxylase induction. Genetic specificity resides in the fraction containing cytochromes P450 and P450. J Biol Chem 248, 7631-7636
48. Nebert DW, Robinson JR, Kon H, 1973, Further studies on genetically mediated differences in monooxygenase activities and spin state of cytochrome P450 iron from rabbit, rat, and mouse liver. J Biol Chem 248, 7637-7647
49. Thompson EB, Benedict WF, Owens IS, Nebert DW, 1974, Aryl hydrocarbon hydroxylase and tyrosine aminotransferase activities in somatic cell hybrids derived from hepatoma tissue culture HTC (rat) cells and 3T3 (mouse) benzo[a]pyrene- resistant cells. Biochem Biophys Res Commun 56, 605-696
50. Nebert DW, Benedict WF, Kouri RE, 1974, Aromatic hydrocarbon-produced tumorigenesis and the genetic differences in aryl hydrocarbon hydroxylase induction. In: Chemical Carcinogenesis (Ts’o POP, DiPaolo JA, eds), pp 271-288, Marcel- Dekker, Inc, New York
51. Robinson JR, Nebert DW, 1974, Genetic expression of aryl hydrocarbon hydroxylase induction. Presence or absence of association with zoxazolamine, diphenylhydantoin, and hexobarbital metabolism. Mol Pharmacol 10, 484-493
52. Nebert DW, 1974, Genetic and environmental factors influencing drug metabolism. In: Perinatal Pharmacology: Problems and Priorities (Dancis J, Hwang JC, eds), pp 49-63, Raven Press, New York
53. Nebert DW, 1974, Genetic and environmental factors influencing placental and fetal metabolism of drugs. In: The Placenta: Biological and Clinical Aspects (Moghissi KS, Hafez ESE, eds), pp 207-237, Charles C Thomas, Springfield, Illinois
54. Poland AP, Glover E, Robinson JR, Nebert DW, 1974, Genetic expression of aryl hydrocarbon hydroxylase activity. Induction of monooxygenase activities and cytochrome P1450 formation by 2,3,7,8-tetrachlorodibenzo-p-dioxin in mice genetically “nonresponsive” to other aromatic hydrocarbons. J Biol Chem 249, 5599-5606
55. Robinson JR, Considine N, Nebert DW, 1974, Genetic expression of aryl hydrocarbon hydroxylase induction. Evidence for the involvement of other genetic loci. J Biol Chem 249, 5851-5859
56. Kouri RE, Ratrie H III, Atlas SA, Niwa A, Nebert DW, 1974, Aryl hydrocarbon hydroxylase induction in human
lymphocyte cultures by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Life Sci 15, 1585-1595
57. Nebert DW, Robinson JR, 1974, Genetic and environmental factors influencing drug metabolism. In: Clinical Drug
Interactions (Morelli J, Sereni S, Cohen S, eds), pp 51-63, Raven Press, New York
58. Nebert DW, 1974, Metabolic activation as a factor in carcinogenic response. In: Carcinogenesis Testing of Chemicals
(Goldberg L, ed), pp 75-78, CRC Press, Cleveland, Ohio
59. Owens IS, Nebert DW, 1975, Aryl hydrocarbon hydroxylase induction in mammalian liver-derived cell cultures. Stimulation
of “cytochrome P1450-associated” enzyme activity by many inducing compounds. Mol Pharmacol 11, 94-104
60. Niwa A, Kumaki K, Nebert DW, Poland AP, 1975, Genetic expression of aryl hydrocarbon hydroxylase activity in the mouse. Distinction between the “responsive” homozygote and heterozygote at the Ah locus. Arch Biochem Biophys 166, 559-564
61. Thorgeirsson SS, Felton JS, Nebert DW, 1975, Genetic differences in the aromatic hydrocarbon-inducible N-hydroxylation of 2-acetylaminofluorene and acetaminophen-produced hepatotoxicity in mice. Mol Pharmacol 11, 159-165
62. Robinson JR, Felton JS, Thorgeirsson SS, Nebert DW, 1975, Pharmacogenetic aspects of drug toxicity and teratogenesis in the newborn. In: Perinatal Pharmacology (Sereni F, Morselli PL, Garattini S, eds), pp 155-169, Raven Press, New York
63. Nebert DW, Felton JS, Robinson JR, 1975, Genetic differences in susceptibility to cancer caused by environmental chemicals. In: Developmental and Genetic Aspects of Drug and Environmental Toxicity (Janku I, ed), pp 82-95, Excerpta Medica, Amsterdam
64. Owens IS, Niwa A, Nebert DW, 1975, Expression of aryl hydrocarbon hydroxylase induction in liver- and hepatoma-derived cell cultures. In: Gene Expression and Carcinogenesis in Cultured Liver (Gerschenson LE, Thompson EB, eds), pp 378- 401, Academic Press, New York
65. Nebert DW, Robinson JR, Niwa A, Kumaki K, Poland AP, 1975, Genetic expression of aryl hydrocarbon hydroxylase activity in the mouse. J Cell Physiol 85, 393-414
66. Nebert DW, Felton JS, 1975, Evidence for the activation of 3-methylcholanthrene as a carcinogen in vivo by cytochrome P1450 from inbred strains of mice. In: Cytochromes P-450 and b5 (Cooper DY, Rosenthal O, Snyder R, Witmer C, eds), pp 127-149, Plenum Publishing Corporation, New York
67. Niwa A, Kumaki K, Nebert DW, 1975, Induction of aryl hydrocarbon hydroxylase activity in various cell cultures by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Mol Pharmacol 11, 399-408
68. Felton JS, Nebert DW, 1975, Mutagenesis of certain activated carcinogens in vitro associated with genetically mediated increases in monooxygenase activity and cytochrome P1450. J Biol Chem 250, 6769-6778
69. Robinson JR, Felton JS, Levitt RC, Thorgeirsson SS, Nebert DW, 1975, Relationship between “aromatic hydrocarbon responsiveness” and the survival times in mice treated with various drugs and environmental compounds. Mol Pharmacol 11, 850-865
70. Shichi H, Atlas SA, Nebert DW, 1975, Genetically regulated aryl hydrocarbon hydroxylase induction in the eye: Possible significance of the drug-metabolizing enzyme system for the retinal pigmented epithelium-choroid. Exp Eye Res 21, 557- 567
71. Atlas SA, Thorgeirsson SS, Boobis AR, Kumaki K, Nebert DW, 1975, Differential induction of murine Ah locus-associated monooxygenase activities in rabbit liver and kidney. Biochem Pharmacol 24, 2111-2116
72. Owens IS, Nebert DW, 1976, Aryl hydrocarbon hydroxylase induction in mammalian liver-derived cell cultures. Effects of various metabolic inhibitors on the enzyme activity in hepatoma cells. Biochem Pharmacol 25, 805-813
73. Haugen DA, Coon MJ, Nebert DW, 1976, Induction of multiple forms of mouse liver cytochrome P-450. Evidence for genetically controlled de novo protein synthesis in response to treatment with $-naphthoflavone or phenobarbital. J Biol Chem 251, 1817-1827
74. Nebert DW, Felton JS, 1976, Importance of genetic factors influencing the metabolism of foreign compounds. Fed Proc 35, 1133-1141
75. Felton JS, Nebert DW, Thorgeirsson SS, 1976, Genetic differences in 2-acetylaminofluorene mutagenicity in vitro associated with mouse hepatic aryl hydrocarbon hydroxylase activity induced by polycyclic aromatic compounds. Mol Pharmacol 12, 225-233
76. Rispin AS, Kon H, Nebert DW, 1976, Electron spin resonance study of oxygen-17 enriched oxybenzo[a]pyrene radical. Mol Pharmacol 12, 476-482
77. Atlas SA, Taylor BA, Diwan BA, Nebert DW, 1976, Inducible monooxygenase activities and 3-methylcholanthrene-initiated tumorigenesis in mouse recombinant inbred sublines. Genetics 83, 537-550
78. Kahl GF, Kahl R, Kumaki K, Nebert DW, 1976, Association of the Ah locus with specific changes in metyrapone and ethylisocyanide binding to mouse liver microsomes. J Biol Chem 251, 5397-5407
79. Atlas SA, Nebert DW, 1976, Genetic association of increases in naphthalene, acetanilide, and biphenyl hydroxylations with inducible aryl hydrocarbon hydroxylase in mice. Arch Biochem Biophys 175, 495-506
80. Shichi H, Tsunematsu Y, Nebert DW, 1976, Aryl hydrocarbon hydroxylase induction in retinal pigmented epithelium: Possible association of genetic difference in a drug-metabolizing enzyme with retinal degeneration. Exp Eye Res 23, 165- 176
81. Atlas SA, Vesell ES, Nebert DW, 1976, Genetic control of interindividual variations in the inducibility of aryl hydrocarbon hydroxylase in human cultured lymphocytes. Cancer Res 36, 4619-4630
82. Niwa A, Nebert DW, 1976, Regulation of enzymatic activities in cultured hepatocytes, with special emphasis on aryl hydrocarbon hydroxylase [in Japanese]. The Tissue Culture 2, 192-197
83. Nebert DW, Thorgeirsson SS, Felton JS, 1976, Genetic differences in mutagenesis, carcinogenesis, and drug toxicity. In: In Vitro Metabolic Activation in Mutagenesis Testing (de Serres FJ, Fouts JR, Bend JR, Philpot RM, eds), pp 105-124, Elsevier/North-Holland Biomedical Press, Amsterdam
84. Atlas SA, Nebert DW, 1976, Pharmacogenetics and human disease. In: Drug Metabolism -- from Microbe to Man (Parke DV, Smith RL, eds), pp 393-430, Taylor and Francis Ltd, London
85. Nebert DW, Thorgeirsson SS, Lambert GH, 1976, Genetic aspects of toxicity during development. Environ Health Perspect 18, 35-45
86. Kumaki K, Jensen NM, Shire JGM, Nebert DW, 1977, Genetic differences in induction of cytosol reduced- NAD(P)H:menadione oxidoreductase and microsomal aryl hydrocarbon hydroxylase in the mouse. J Biol Chem 252, 157- 165
87. Nebert DW, Atlas SA, 1977, Aryl hydrocarbon hydroxylase induction (Ah locus) as a possible genetic marker for cancer. In: Genetics of Human Cancer (Mulvihill JJ, Miller RW, Fraumeni JF Jr, eds), pp 301-318, Raven Press, New York
88. Nebert DW, Boobis AR, Yagi H, Jerina DM, Kouri RE, 1977, Genetic differences in mouse cytochrome P1-450-mediated metabolism of benzo[a]pyrene in vivo. In: Biological Reactive Intermediates (Jollow DJ, Kocsis JJ, Snyder R, Vainio H, eds), pp 125-145, Plenum Publishing Corporation, New York
89. Boobis AR, Nebert DW, Felton JS, 1977, Comparison of $-naphthoflavone and 3-methylcholanthrene as inducers of hepatic cytochrome(s) P-448 and aryl hydrocarbon (benzo[a]pyrene) hydroxylase activity. Mol Pharmacol 13, 259-268
90. Thorgeirsson SS, Nebert DW, 1977, The Ah locus and the metabolism of chemical carcinogens and other foreign compounds. Advanc Cancer Res 25, 149-193
91. Boobis AR, Nebert DW, Genetic differences in the metabolism of carcinogens and in the binding of benzo[a]pyrene metabolites to DNA. Advanc Enz Regul 1977; 15: 339–362
92. Nebert DW, Kumaki K, Sato M, Kon H, 1977, Association of Type I, Type II, and Reverse Type I difference spectra with absolute spin state of cytochrome P-450 iron. In: Microsomes and Drug Oxidations (Ullrich V, Roots I, Hildebrandt A, Estabrook RW, Conney AH, eds), pp 224-231, Pergamon Press, Oxford, England
93. Atlas SA, Boobis AR, Felton JS, Thorgeirsson SS, Nebert DW, 1977, Ontogenetic expression of polycyclic aromatic compound-inducible monooxygenase activities and forms of cytochrome P-450 in the rabbit. Evidence for temporal control and organ specificity of two genetic regulatory systems. J Biol Chem 252, 4712-4721
94. Sato M, Kon H, Kumaki K, Nebert DW, 1977, Comparative EPR study on high-spin ferric porphine complexes and cytochrome P450 having rhombic character. Biochim Biophys Acta 498, 403-421
95. Lambert GH, Nebert DW, 1977, Genetically mediated induction of drug-metabolizing enzymes associated with congenital defects in the mouse. Teratology 16, 147-153
96. Kano I, Gielen JE, Yagi H, Jerina DM, Nebert DW, 1977, Aryl hydrocarbon hydroxylase induction in cell culture: Metabolism of the polycyclic hydrocarbon inducer is not required. Mol Pharmacol 13, 1181-1186
97. Nebert DW, Levitt RC, Orlando MM, Felton JS, 1977, Effects of environmental chemicals on the genetic regulation of microsomal enzyme systems. Clin Pharmacol Ther 22, 640-658
98. Kouri RE, Nebert DW, 1977, Genetic regulation of susceptibility to polycyclic hydrocarbon-induced tumors in the mouse. In: Origins of Human Cancer (Hiatt HH, Watson JD, Winsten JA, eds), vol 4, pp 811-835, Cold Spring Harbor Laboratory, New York
99. Nebert DW, Levitt RC, Jensen NM, Lambert GH, Felton JS, 1977, Birth defects and aplastic anemia: Differences in polycyclic hydrocarbon toxicity associated with the Ah locus. Arch Toxicol 39, 109-132
100. Guenthner TM, Nebert DW, 1977, The cytosolic receptor for aryl hydrocarbon hydroxylase induction by polycyclic aromatic compounds. Evidence for structural and regulatory variants among established cell culture lines. J Biol Chem 252, 8981-8989
101. Levitt RC, Legraverend C, Nebert DW, Pelkonen O, 1977, Effects of harman and norharman on the mutagenicity and binding to DNA of benzo[a]pyrene metabolites in vitro and on aryl hydrocarbon hydroxylase induction in cell culture. Biochem Biophys Res Commun 79, 1167-1175
102. Nebert DW, 1977, Genetic differences in the toxicity of drugs and chemical carcinogens. In: Proceedings of the Eighth Conference on Environmental Toxicology, pp 98-123, Wright-Patterson Air Force Base, Dayton, Ohio
103. Kumaki K, Sato M, Kon H, Nebert DW, 1978, Correlation of Type I, Type II, and Reverse Type I difference spectra with absolute spin state of hepatic microsomal cytochrome P-450 iron in five mammalian species. J Biol Chem 253, 1048-1058
104. Atlas SA, Nebert DW, 1978, Pharmacogenetics: A possible pragmatic perspective in neoplasm predictability. Sem Oncol 5, 89-106
105. Pelkonen O, Boobis AR, Yagi H, Jerina DM, Nebert DW, 1978, The tentative identification of benzo[a]pyrene metabolite- nucleoside complexes produced in vitro by mouse liver microsomes. Mol Pharmacol 14, 306-322
106. Shichi H, Gaasterland DE, Jensen NM, Nebert DW, 1978, The Ah locus: Genetic differences in susceptibility to cataracts induced by acetaminophen. Science 200, 539-541
107. Shichi H, Kumaki K, Nebert DW, 1978, Circular dichroism studies on the binding of Type I substrates and Reverse Type I compounds to rabbit liver microsomal cytochrome P-450. Chem-Biol Interactions 20, 133-148
108. Nebert DW, 1978, Genetic differences affecting microsomal electron transport: The Ah locus. Methods Enzymol 52, 226- 240
109. Nebert DW, 1978, Genetic control of drug metabolism. In: Pharmacological Intervention of the Aging Process (Roberts J, Cristofalo V, Adelman RC, eds), pp 55-79, Plenum Publishing Corporation, New York
110. Pelkonen O, Boobis AR, Nebert DW, 1978, Genetic differences in the binding of reactive carcinogenic metabolites to DNA. In: Carcinogenesis: Polynuclear Aromatic Hydrocarbons (Jones PW, Freudenthal RI, eds), vol 3, pp 383-400, Raven Press, New York
111. Gielen JE, Heusghem C, Nebert DW, 1978, Mecanisme de l'induction de l'hydroxylase des hydrocarbures aromatiques (AHH) [in French]. In: Mises au point de Biochimie Pharmacologique (Siest G, Heusghem C, eds), pp 105-126, Masson, Paris
112. Owens IS, Nebert DW, Liem HH, Müller-Eberhard U, 1978, Hemopexin and aryl hydrocarbon hydroxylase induction in the mouse and in cell culture. Biochem Pharmacol 27, 1665-1669
113. Boobis AR, Atlas SA, Nebert DW, 1978, Carcinogenic benzo[a]pyrene metabolites bound to DNA: Metabolic formation by human cultured lymphocytes and by human liver microsomes. Pharmacology 17, 241-248
114. Kumaki K, Nebert DW, 1978, Spectral evidence for weak ligand in sixth position of hepatic microsomal cytochrome P-450 iron in vivo. Pharmacology 17, 262-279
115. Kouri RE, Rude TH, Joglekar R, Dansette PM, Jerina DM, Atlas SA, Owens IS, Nebert DW, 1978, 2,3,7,8- Tetrachlorodibenzo-p-dioxin: cocarcinogen which enhances 3-methylcholanthrene-initiated subcutaneous tumors in mice genetically “nonresponsive” at the Ah locus. Cancer Res 38, 2777-2783
116. Hjelmeland LM, Nebert DW, Chrambach A, 1978, Electrophoresis and electrofocusing of native membrane proteins. In: Electrophoresis (Catsimpoola N, ed), pp 29-56, Elsevier/North-Holland, Inc, New York
117. Nebert DW, Atlas SA, Guenthner TM, Kouri RE, 1978, The Ah locus: Genetic regulation of the enzymes which metabolize polycyclic hydrocarbons and the risk for cancer. In: Polycyclic Hydrocarbons and Cancer: Chemistry, Molecular Biology and Environment (Ts’o POP, Gelboin HV, eds), pp 345-390, Academic Press, New York
118. Nebert DW, Atlas SA, 1978, The Ah locus: Aromatic hydrocarbon responsiveness ... of mice and men. Hum Genet Suppl. 1, 149-160
119. Guenthner TM, Nebert DW, 1978, Evidence in rat and mouse liver for temporal control of two forms of cytochrome P-450 inducible by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Eur J Biochem 91, 449-456
120. Nebert DW, 1978, Genetic control of carcinogen metabolism leading to individual differences in cancer risk. Biochimie 60, 1019-1029
121. Nebert DW, Shum S, Boobis AR, Atlas SA, 1978, Developmental pharmacology and the Ah locus: Regulatory and temporal genes affecting teratogenesis. In: Advances in Pharmacology and Therapeutics: Drug-Action Modifications-- Comparative Pharmacology (Oliver E, ed), vol 8, pp 81-90, Pergamon Press Ltd., Oxford, England
122. Nebert DW, Owens IS, Kano I, Guenthner TM, 1978, Aryl hydrocarbon hydroxylase. Evidence of receptors for induction process in cell culture. In: Advances in Pharmacology and Therapeutics: Chemotherapy (Adolphe M, ed), vol 10, pp 185-196, Pergamon Press Ltd, Oxford, England
123. Nebert DW, 1978, Possible relationship between genetic differences in drug metabolism and teratogenesis. In: Safe Drugs for Canadian Children (Crichton JU, ed), pp 48-77, Ross Pediatrics Press, Cleveland, Ohio
124. Nebert DW, Jensen NM, 1979, Benzo[a]pyrene-initiated leukemia in mice. Association with allelic differences at the Ah locus. Biochem Pharmacol 27, 149-151
125. Boobis AR, Nebert DW, Pelkonen O, 1979, The effects of microsomal enzyme inducers in vivo and inhibitors in vitro on the covalent binding of benzo[a]pyrene metabolites to DNA catalyzed by liver microsomes from genetically responsive and nonresponsive mice. Biochem Pharmacol 28, 111-121
126. Nebert DW, Levitt RC, Pelkonen O, 1979, Genetic variation in metabolism of chemical carcinogens associated with susceptibility to tumorigenesis. In: Carcinogens: Identification and Mechanisms of Action (Griffin AC, Shaw CR, eds), pp 157-185, Raven Press, New York
127. Nebert DW, 1979, Genetic aspects of enzyme induction by drugs and chemical carcinogens. In: The Induction of Drug Metabolism - “Symposia Medica Hoechst” (Estabrook RW, Lindenlaub E, eds), vol 14, pp 419-452, FK Schattauer Verlag, Stuttgart and New York
128. Vähäkängas K, Nebert DW, Pelkonen O, 1979, The DNA binding of benzo[a]pyrene metabolites catalyzed by rat lung microsomes in vitro and in isolated perfused rat lung. Chem-Biol Interactions 24, 167-176
129. Ahokas JT, Saarni H, Nebert DW, Pelkonen O, 1979, The in vitro metabolism and covalent binding of benzo[a]pyrene to DNA catalysed by trout liver microsomes. Chem-Biol Interactions 25, 103-111
130. Kahl GE, Klaus E, Legraverend C, Nebert DW, Pelkonen O, 1979, Formation of benzo[a]pyrene metabolite-nucleoside adducts in isolated perfused rat and mouse liver and in mouse lung slices. Biochem Pharmacol 28, 1051-1056
131. Levitt RC, Pelkonen O, Okey AB, Nebert DW, 1979, Genetic differences in metabolism of polycyclic aromatic carcinogens and aromatic amines by mouse liver microsomes. Detection by DNA binding of metabolites and by mutagenicity in histidine-dependent Salmonella typhimurium in vitro. J Natl Cancer Inst 62, 947-955
132. Nebert DW, Jensen NM. The Ah locus: Genetic regulation of the metabolism of carcinogens, drugs, and other environmental chemicals by cytochrome P-450-mediated monooxygenases. CRC Crit Rev Biochem 1979; 6: 401–437
133. Guenthner TM, Nebert DW, Menard RH, 1979, Microsomal aryl hydrocarbon hydroxylase in rat adrenal: Regulation by ACTH but not by polycyclic hydrocarbons. Mol Pharmacol 15, 719-728
134. Hjelmeland LM, Nebert DW, Chrambach A, 1979, Electrofocusing of integral membrane proteins in mixtures of zwitterionic and nonionic detergents. Anal Biochem 95, 201-208
135. Guenthner TM, Negishi M, Nebert DW, 1979, Separation of acetanilide and its hydroxylated metabolites and quantitative determination of "acetanilide 4-hydroxylase activity" by high-pressure liquid chromatography. Anal Biochem 96, 201-207
136. Nebert DW, 1979, The Ah locus: A gene with possible importance in cancer predictability. Drug Ther 4, 39-49
137. Pelkonen O, Boobis AR, Levitt RC, Kouri RE, Nebert DW, 1979, Genetic differences in the metabolic activation of benzo[a]pyrene in mice. Attempts to correlate tumorigenesis with binding of reactive intermediates to DNA and with mutagenesis in vitro. Pharmacology 18, 281-293
138. Boobis AR, Kouri RE, Nebert DW, 1979, Genetic differences in the binding of benzo[a]pyrene metabolites to DNA in the mouse. Cancer Detect Prev 2, 83-111
139. Nebert DW, 1979, Genetic differences in the induction of monooxygenase activities by polycyclic aromatic compounds. Pharmacol Ther 6, 395-417
140. Guenthner TM, Fysh JM, Nebert DW, 1979, 2,3,7,8-Tetrachlorodibenzo-p-dioxin: Covalent binding of reactive metabolic intermediates principally to protein in vitro. Pharmacology 19, 12-22
141. Nebert DW, Shum S, Boobis AR, Atlas SA, 1979, Developmental pharmacology and the Ah locus: Regulatory and temporal genes affecting teratogenesis. Acta Biol Med Germ 38, 519-529
142. Levitt RC, Fysh JM, Jensen NM, Nebert DW, 1979, The Ah locus: Biochemical basis for genetic differences in brain tumor formation in mice. Genetics 92, 1205-1210
143. Nebert DW, 1979, Multiple forms of inducible drug-metabolizing enzymes. A reasonable mechanism by which any organism can cope with adversity. Mol Cell Biochem 27, 27-46
144. Negishi M, Nebert DW, 1979, Structural gene products of the Ah locus. Genetic and immunochemical evidence for two forms of mouse liver cytochrome P-450 induced by 3-methylcholanthrene. J Biol Chem 254, 11015-11023
145. Okey AB, Bondy GP, Mason ME, Kahl GF, Eisen HJ, Guenthner TM, Nebert DW, 1979, Regulatory gene product of the Ah locus. Characterization of the cytosolic inducer-receptor complex and evidence for its nuclear translocation. J Biol Chem 254, 11636-11648
146. Nebert DW, Bigelow SW, Okey AB, Yahagi T, Mori Y, Nagao M, Sugimura T, 1979, Pyrolysis products from amino acids
and protein: Highest mutagenicity requires cytochrome P1-450. Proc Natl Acad Sci USA 76, 5979-5983
147. Shum S, Jensen NM, Nebert DW, 1979, The Ah locus: In utero toxicity and teratogenesis associated with genetic
differences in benzo[a]pyrene metabolism. Teratology 20, 365-376
148. Fysh JM, Andrews LS, Pohl LR, Nebert DW, 1980, Differing degrees of coal-tar shampoo-induced mutagenesis in the
Salmonella/liver test system in vitro. Pharmacology 20, 1-8
149. Guenthner TM, Kahl GF, Nebert DW, 1980, NADPH-cytochrome P-450 reductase: preferential inhibition by ellipticine
and other Type II compounds having little effect on NADPH-cytochrome c reductase. Biochem Pharmacol 29, 89-95
150. Legraverend C, Nebert DW, Boobis AR, Pelkonen O, 1980, DNA binding of benzo[a]pyrene metabolites: Effects on
substrate and microsomal protein concentration in vitro and diet and tissue differences in vivo. Pharmacology 20, 137-148
151. Kahl GF, Friederici D, Bigelow SW, Okey AB, Nebert DW, 1980, Ontogenetic expression of regulatory and structural gene products associated with the Ah locus. Comparison of rat, mouse, rabbit, and Sigmoden hispedis. Dev Pharmacol Ther 1, 137-162
152. Nebert DW, 1980, The Ah locus. A gene with possible importance in cancer predictability. Arch Toxicol Suppl 3, 195-207
153. Nebert DW, Jensen NM, Levitt RC, Felton JS, 1980, Toxic chemical depression of the bone marrow and possible aplastic
anemia explainable on a genetic basis. Clin Toxicol 16, 99-122
154. Shichi H, Tanaka Y, Jensen NM, Nebert DW, 1980, Genetic differences in cataract and other ocular abnormalities induced
by paracetamol and naphthalene. Pharmacology 20, 229-241
155. Legraverend C, Mansour B, Nebert DW, Holland JM, 1980, Genetic differences in benzo[a]pyrene-initiated tumorigenesis
in mouse skin. Pharmacology 20, 242-255
156. Pelkonen O, Vähäkängas K, Nebert DW, 1980, Binding of polycyclic aromatic hydrocarbons to DNA, comparison to
mutagenesis and tumorigenesis. J Toxicol Environ Health 6, 1009-1020
157. Nebert DW, 1980, Pharmacogenetics: An approach to understanding chemical and biologic aspects of cancer. J Natl
Cancer Inst 64, 1279-1290
158. Nebert DW, 1980, Human genetic variation in the enzymes of detoxication. In: Enzymatic Basis of Detoxication (Jakoby
WB, ed), vol 1, pp 25-68, Academic Press, New York
159. Nebert DW, 1980, Genetic differences in drug metabolism: Possible importance in teratogenesis. In: Phenytoin-Induced Teratology and Gingival Pathology (Hassell TM, Johnston MC, Dudley KH, eds), pp 113-128, Raven Press Books Ltd, New York
160. Negishi M, Nebert DW, 1980, Structural gene products of the murine Ah locus: Immunochemical characterization of two forms of P-450 induced by polycyclic aromatic compounds. In: Microsomes, Drug Oxidations, and Chemical Carcinogenesis (Coon MJ, Conney AH, Estabrook RW, Gelboin HV, Gillette JR, O'Brien PJ, eds), vol I, pp 155-158, Academic Press, New York
161. Nebert DW, 1980, The Ah locus: Genetic differences in toxic and tumorigenic response to foreign compounds. In: Microsomes, Drug Oxidations, and Chemical Carcinogenesis (Coon MJ, Conney AH, Estabrook RW, Gelboin HV, Gillette JR, O'Brien PJ, eds), vol II, pp 801-812, Academic Press, New York
162. Shichi H, Nebert DW, 1980, Drug metabolism in ocular tissues. In: Extrahepatic Metabolism of Drugs and Other Foreign Compounds (Gram TE, ed), vol 5, pp 333-363, Spectrum Publications, Inc, Jamaica, New York
163. Galloway SM, Perry PE, Meneses J, Nebert DW, Pedersen RA, 1980, Cultured mouse embryos metabolize benzo[a]pyrene during early gestation: Genetic differences detectable by sister chromatid exchange. Proc Natl Acad Sci USA 77, 3524- 3528
164. Atlas SA, Zweier JL, Nebert DW, 1980, Genetic differences in phenytoin pharmacokinetics. In vivo clearance and in vitro
metabolism among inbred strains of mice. Dev Pharmacol Ther 1, 281-304
165. Nebert DW, Jensen NM, Perry JW, Oka T, 1980, Association between ornithine decarboxylase induction and the Ah locus
in mice treated with polycyclic aromatic compounds. J Biol Chem 255, 6836-6842
166. Kouri RE, Schechtman LM, Nebert DW, 1980, Metabolism of chemical carcinogens. In: Genetic Differences in
Chemical Carcinogenesis (Kouri RE, ed), pp 21-66, CRC Press, Inc, Boca Raton, Florida
167. Kano I, Nebert DW, 1980, Subcellular localization of membrane-bound aryl hydrocarbon hydroxylase and NAD(P)H-
dependent reductase activities in mouse liver. Eur J Biochem 109, 25-31
168. Mattison DR, Nebert DW, Lang MA, 1980, Multiple forms of murine hepatic microsomal cytochrome P-450 responsible for monooxygenation of estradiol-17β, benzo[a]pyrene, acetanilide, and ethylmorphine. In: Biochemistry, Biophysics and Regulation of Cytochrome P-450 (Gustafsson JÅ, Carlstedt-Duke J, Mode A, Rafter J, eds), vol 13, pp 255-258, Elsevier/North-Holland Biomedical Press, Amsterdam
169. Lang MA, Nebert DW, Negishi M, 1980, Structural gene products of the Ah complex. Separation of multiple forms of liver microsomal cytochrome P-450 and characterization of mRNA associated with P1-450 from 3-methylcholanthrene-treated mice. In: Biochemistry, Biophysics and Regulation of Cytochrome P-450 (Gustafsson JÅ, Carlstedt-Duke J, Mode A, Rafter J, eds), vol 13, pp 415-422, Elsevier/North-Holland Biomedical Press, Amsterdam
170. Nebert DW, 1980, Closing remarks: Where have we been, where are we now, and where should we go? In: Biochemistry, Biophysics and Regulation of Cytochrome P-450 (Gustafsson JÅ, Carlstedt-Duke J, Mode A, Rafter J, eds), vol 13, pp 609-621, Elsevier/North-Holland Biomedical Press, Amsterdam
171. Felton JS, Ketley JN, Jakoby WB, Aitio A, Bend JR, Nebert DW, 1980, Hepatic glutathione transferase activity induced by polycyclic aromatic compounds. Lack of correlation with the murine Ah locus. Mol Pharmacol 18, 559-564
172. Okey AB, Bondy GP, Mason ME, Nebert DW, Forster-Gibson C, Muncan J, Dufresne MJ, 1980, Temperature-dependent cytosol-to-nucleus translocation of the Ah receptor for 2,3,7,8-tetrachlorodibenzo-p-dioxin in continuous cell culture lines. J Biol Chem 255, 11415-11422
173. Nebert DW, Shum S, 1980, What does “nondetectable,” or “zero,” really mean? -- Reply to the letter of Doctors Shepard and Fantel. Teratology 22, 349-350
174. Nebert DW, Shum S, 1980, The murine Ah locus: Genetic differences in birth defects among individuals in the same uterus. In: Etiology of Cleft Lip and Cleft Palate, Volume on "Progress in Clinical and Biological Research" (Melnick M, Bixler D, Shields E, eds), vol 46, pp 173-196, Alan R. Liss, Inc, New York
175. Eisen HJ, Nebert DW, Okey AB, 1980, Genetics and biological response to environmental toxic agents. In: Environmental Health Chemistry - The Chemistry of Environmental Agents as Potential Human Hazards (McKinney JD, ed), pp 101-122, Ann Arbor Science Publishers, Inc, Ann Arbor, Michigan
176. Nebert DW, Eisen HJ, Negishi M, Lang MA, Hjelmeland LM, Okey AB, 1981, Genetic mechanisms controlling the induction of polysubstrate monooxygenase (P-450) activities. Annu Rev Pharmacol Toxicol 21, 431-462
177. Nebert DW, 1981, Selected aspects of pharmacogenetics. In: The Mouse in Biomedical Research (Foster HL, Small JD, Fox JG, eds), vol I, pp 285-298, Academic Press, New York
178. Negishi M, Swan DC, Enquist LW, Nebert DW, 1981, Isolation and characterization of a cloned DNA sequence associated with the murine Ah locus and a 3-methylcholanthrene-induced form of cytochrome P-450. Proc Natl Acad Sci USA 78, 800-804
179. Negishi M, Nebert DW, 1981, Structural gene products of the Ah complex. Large increases in mRNA from mouse liver associated with cytochrome P1-450 induction by 3-methylcholanthrene. J Biol Chem 256, 3085-3091
180. Negishi M, Jensen NM, Garcia GS, Nebert DW, 1981, Structural gene products of the murine Ah locus. Differences in ontogenesis, membrane location, and glucosamine incorporation between liver microsomal cytochromes P1-450 and P-448 induced by polycyclic aromatic compounds. Eur J Biochem 115, 585-594

181. Hannah RR, Nebert DW, Eisen HJ, 1981, Regulatory gene product of the Ah complex. Comparison of 2,3,7,8- tetrachlorodibenzo-p-dioxin and 3-methylcholanthrene binding to several moieties in mouse liver cytosol. J Biol Chem 256, 4584-4590
182. Nebert DW, 1981, Genetic differences in susceptibility to chemically induced myelotoxicity and leukemia. Environ Health Perspect 39, 11-22 PMID: 7016519
183. Nebert DW, 1981, Birth defects and the potential role of genetic differences in drug metabolism. In: Birth Defects: Original Article Series (Bloom AD, James LS, eds), vol XVII, pp 51-70, Alan R Liss, Inc, New York
184. Nebert DW, 1981, Genetic differences in the induction of monooxygenase activities by polycyclic aromatic compounds. In: International Encyclopedia of Pharmacology and Therapeutics, Volume on “Characteristics of the Mammalian Hepatic Monooxygenases” (Schenkman JB, Kupfer D, eds), Chapter 9, pp 269-291, Pergamon Press, New York
185. Tukey RH, Nebert DW, Negishi M , 1981, Structural gene product of the Ah complex. Evidence for transcriptional control of cytochrome P1-450 induction by use of a cloned DNA sequence. J Biol Chem 256, 6969-6974
186. Kano I, Nebert DW, 1981, Ornithine decarboxylase induction in liver- and hepatoma-derived cell cultures. No detectable differences between control and 3-methylcholanthrene-treated cells. Mol Pharmacol 20, 172-178
187. Nebert DW, 1981, Possible clinical importance of genetic differences in drug metabolism. Brit Med J 283, 537-542
188. Nebert DW, 1981, Etiology of birth defects. Potential importance of genetic differences in drug metabolism. In: Drug
Metabolism in the Immature Human (Soyka LF, Redmond GP, eds), pp 1-17, Raven Press, New York
189. Lang MA, Nebert DW, 1981, Structural gene products of the Ah locus. Evidence for many unique P-450-mediated monooxygenase activities reconstituted from 3-methylcholanthrene-treated C57BL/6N mouse liver microsomes. J Biol Chem 256, 12058-12067
190. Lang MA, Gielen JE, Nebert DW, 1981, Genetic evidence for many unique liver microsomal P-450-mediated monooxygenase activities in heterogeneic stock mice. J Biol Chem 256, 12068-12075
191. Bigelow SW, Nebert DW, 1982, The Ah regulatory gene product. Survey of nineteen polycyclic aromatic compounds' and fifteen benzo[a]pyrene metabolites' capacity to bind to the cytosolic receptor. Toxicol Lett 10, 109-118
192. Nebert DW, Negishi M, Lang MA, Hjelmeland LM, Eisen HJ, 1982, The Ah locus, a multigene family necessary for survival in a chemically adverse environment: Comparison with the immune system. Advanc Genet 21, 1-52
193. Nebert DW, Jensen NM, Shinozuka H, Kunz HW, Gill TJ, 1982, The Ah phenotype. Survey of forty-eight rat strains and twenty inbred mouse strains. Genetics 100, 79-87
194. Chen YT, Lang MA, Jensen NM, Negishi M, Tukey RH, Sidransky E, Guenthner TM, Nebert DW, 1982, Similarities between mouse and rat liver microsomal cytochromes P-450 induced by 3-methylcholanthrene. Evidence from catalytic, immunologic, and recombinant DNA studies. Eur J Biochem 122, 361-368
195. Nebert DW, Bigelow SW, 1982, Genetic control of drug metabolism: Relationship to birth defects. Sem Perinatol 6, 105- 115
196. Shichi H, Nebert DW, 1982, Organ toxicity: Eye and other special sensory organs. Environ Health Perspect 44, 107-117
197. Legraverend C, Hannah RR, Eisen HJ, Owens IS, Nebert DW, Hankinson O, 1982, Regulatory gene product of the Ah
locus: Characterization of receptor mutants among mouse hepatoma clones. J Biol Chem 257, 6402-6407
198. Estabrook RW, Coon MJ, Sato R, Conney AH, Gustafsson JÅ, Omura T, Nebert DW, 1982, Heralded highlights and harbingers of hope. In: Microsomes, Drug Oxidations, and Drug Toxicity (Sato R, Kato K, eds), pp 3-11, Japan Scientific Societies Press, Tokyo
199. Tukey RH, Nakamura M, Chen YT, Negishi M, Nebert DW, 1982, Genetic regulation of P-450 induction in the mouse. Studies with a cloned DNA sequence. In: Microsomes, Drug Oxidations, and Drug Toxicity (Sato R, Kato K, eds), pp 353-360, Japan Scientific Societies Press, Tokyo
200. Lang MA, Chen YT, Tukey RH, Sidransky E, Negishi M, Nebert DW, 1982, Rat liver “P1-450” and “P-448” appear to be very similar to these same two cytochromes in mouse liver. In: Microsomes, Drug Oxidations, and Drug Toxicity (Sato R, Kato K, eds), pp 575-576, Japan Scientific Societies Press, Tokyo
201. Negishi M, Chen YT, Tukey RH, Kisliuk BM, Nebert DW, 1982, Expression and subcellular distribution of mouse P1-450 mRNA, as determined by molecular hybridization with cloned P1-450 DNA. In: Microsomes, Drug Oxidations, and Drug Toxicity (Sato R, Kato K, eds), pp 577-578, Japan Scientific Societies Press, Tokyo
202. Pelkonen O, Nebert DW, 1982, Metabolism of polycyclic aromatic hydrocarbons: Etiologic role in carcinogenesis. Pharmacol Rev 34, 189-222
203. Nebert DW, Negishi M, 1982, Multiple forms of cytochrome P-450 and the importance of molecular biology and evolution. Biochem Pharmacol 31, 2311-2317
204. Nebert DW, Negishi M, Enquist LW, Swan DC, 1982, Use of recombinant DNA technology in the study of genetic differences in drug metabolism affecting individual risk of malignancy. In: Mechanisms of Chemical Carcinogenesis (Harris CC, Cerutti PA, eds), vol 2, pp 351-362, Alan R. Liss, Inc, New York
205. Nebert DW, 1982, The importance of genetics in the metabolism and fate of mutagens and promutagens. J Environ Sci Health A17, 559-566
206. Chen YT, Negishi M, Nebert DW, 1982, Cytochrome P1-450 structural gene in mouse, rat and rabbit. Differences in DNA methylation and developmental expression of mRNA. DNA 1, 231-238
207. Tukey RH, Hannah RR, Negishi M, Nebert DW, Eisen HJ, 1982, The Ah locus. Correlation of intranuclear appearance of inducer-receptor complex with induction of cytochrome P1-450 mRNA. Cell 31, 275-284
208. Tukey RH, Negishi M, Nebert DW, 1982, Quantitation of hepatic cytochrome P1-450 mRNA with the use of a cloned DNA probe. Effects of various P-450 inducers in C57BL/6N and DBA/2N mice. Mol Pharmacol 22, 779-786
209. Okey AB, Nebert DW, 1982, The Ah gene complex: A model for studying specific interactions of carcinogens and toxic chemicals. In: Workshop on the Combined Effects of Xenobiotics (Stich HF, Leung HW, Roberts JR, eds), pp 37-66, National Research Council of Canada, Ottawa, Canada
210. Kärenlampi SO, Eisen HJ, Nebert DW, 1982, Binding affinity of P1-450 inducers for the Ah receptor does not correlate with the inhibition of epidermal growth factor (EGF) binding to cell-surface receptors. In: Cytochrome P-450, Biochemistry, Biophysics and Environmental Implications (Hietanen E, Laitinen M, Hänninen O, eds), pp 91-94, Elsevier/North-Holland Biomedical Press, Amsterdam
211. Nebert DW, 1982, Fundamental principles of cloning. In: Cytochrome P-450, Biochemistry, Biophysics and Environ- mental Implications (Hietanen E, Laitinen M, Hänninen O, eds), pp 109-117, Elsevier/North-Holland Biomedical Press, Amsterdam
212. Negishi M, Altieri M, Nakamura M, Ikeda T, Chen YT, Ohyama T, Nebert DW, 1982, Isolation and characterization of the mouse P1-450 chromosomal gene. In: Cytochrome P-450, Biochemistry, Biophysics and Environmental Implications (Hietanen E, Laitinen M, Hänninen O, eds), pp 119-126, Elsevier/North-Holland Biomedical Press, Amsterdam
213. Ohyama T, Nebert DW, Negishi M, 1982, Genetic regulation of mouse liver microsomal P2-450 induction by isosafrole (ISF) and 3-methylcholanthrene (MC). In: Cytochrome P-450, Biochemistry, Biophysics and Environmental Implications (Hietanen E, Laitinen M, Hänninen O, eds), pp 177-180, Elsevier/North-Holland Biomedical Press, Amsterdam
214. Ikeda T, Altieri M, Nakamura M, Nebert DW, Negishi M, 1982, Induction by 3-methylcholanthrene (MC) or isosafrole (ISF) of two P-450 mRNA's which share sequence homology. In: Cytochrome P-450, Biochemistry, Biophysics and Environmental Implications (Hietanen E, Laitinen M, Hänninen O, eds), pp 181-184, Elsevier/North-Holland Biomedical Press, Amsterdam

215. Lang MA, Negishi M, Stupans I, Nebert DW, 1982, Purification and characterization of PJ-450 from mouse liver microsomes. In: Cytochrome P-450, Biochemistry, Biophysics and Environmental Implications (Hietanen E, Laitinen M, Hänninen O, eds), pp 391-394, Elsevier/North-Holland Biomedical Press, Amsterdam
216. Legraverend C, Hannah RR, Eisen HJ, Owens IS, Nebert DW, Hankinson O, 1982, Characterization of Ah receptor mutants among benzo[a]pyrene-resistant mouse hepatoma clones. In: Cytochrome P-450, Biochemistry, Biophysics and Environmental Implications (Hietanen E, Laitinen M, Hänninen O, eds), pp 567-572, Elsevier/North-Holland Biomedical Press, Amsterdam
217. Nebert DW, 1982, Pharmacogenetics and human cancer. In: Host Factors in Human Carcinogenesis (Armstrong B, Bartsch H, eds), pp 365-380, International Agency for Research on Cancer Scientific Publications, Nm 39, Lyon, France
218. Nebert DW, Negishi M, Eisen HJ, 1983, Genetic differences in enzymes which metabolize drugs, chemical carcinogens, and other environmental pollutants. In: Human and Environmental Risks of Chlorinated Dioxins and Related Compounds (Tucker RE, Young AL, Gray AP, eds), pp 441-462, Plenum Publishing Corporation, New York
219. Nebert DW, Elashoff JD, Wilcox KR Jr, 1983, Possible effect of neonatal polybrominated biphenyl exposure on the developmental abilities of children. Am J Public Health 73, 286-289 PMID: 6297322
220. Eisen HJ, Hannah RR, Legraverend C, Okey AB, Nebert DW, 1983, The Ah receptor: Controlling factor in the induction of drug-metabolizing enzymes by certain chemical carcinogens and other environmental pollutants. In: Biochemical Actions of Hormones (Litwack G, ed), vol X, pp 227-258, Academic Press, New York
221. Nebert DW, 1983, Genetic differences in drug metabolism: Proposed relationship to human birth defects. In: Handbook of Teratology and Reproductive Toxicology (Johnson EM, Kochhar DM, eds), vol 65, pp 49-62, Springer-Verlag, New York
222. Nebert DW, Chen YT, Negishi M, Tukey RH, 1983, Cloning genes that encode drug-metabolizing enzymes. Developmental pharmacology and teratology. In: Developmental Pharmacology (MacLeod SM, Okey AB, Spielberg SP, eds), pp 61–79, Alan R Liss, Inc, New York
223. Okey AB, Nebert DW, 1983, Hepatic drug-metabolizing enzymes during embryonic and fetal development. In: Pediatric Liver Disease (Fisher MM, Roy CC, eds), vol. 5, pp 55-93, Plenum Publishing Corporation, New York
224. Hjelmeland LM, Nebert DW, Osborne JC Jr, 1983, Sulfobetaine derivatives of bile acids: Nondenaturing surfactants for membrane biochemistry. Anal Biochem 130, 72-82
225. Lubet RA, Connolly GM, Nebert DW, Kouri RE, 1983, Dibenzo[a,h]anthracene-induced subcutaneous tumors in mice. Strain sensitivity and the role of carcinogen metabolism. Carcinogenesis 4, 513-517
226. Ikeda T, Altieri M, Chen YT, Nakamura M, Tukey RH, Nebert DW, Negishi M, 1983, Characterization of P2-450 (20 S) mRNA. Association with the P1-450 genomic gene and differential response to the inducers 3-methylcholanthrene and isosafrole. Eur J Biochem 134, 13-18
227. Nakamura M, Negishi M, Altieri M, Chen YT, Ikeda T, Tukey RH, Nebert DW, 1983, Structure of the mouse cytochrome P1-450 genomic gene. Eur J Biochem 134, 19-25
228. Chen YT, Bigelow SW, Levitt RC, Nebert DW, 1983, Screening of 16 common therapeutic drugs: Possible association with the Ah locus. Dev Pharmacol Ther 6, 269-283
229. Kärenlampi SO, Eisen HJ, Hankinson O, Nebert DW, 1983, Effects of cytochrome P1-450 inducers on the cell-surface receptors for epidermal growth factor, phorbol 12,13-dibutyrate, or insulin of cultured mouse hepatoma cells. J Biol Chem 258, 10378-10383
230. Kaipainen P, Nebert DW, Lang MA, 1983, Comparison of coumarin 7-hydroxylase activities in kidney and liver of DBA/2J and C57BL/6J mice. In: Extrahepatic Drug Metabolism and Chemical Carcinogenesis (Rydström J, Montelius J, Bengtsson M, eds), pp 27-28, Elsevier/North-Holland Biomedical Press, Amsterdam
231. Nebert DW, Tukey RH, Mackenzie PI, Negishi M, Eisen HJ, 1983, Several P-450 genes regulated by the Ah receptor. In: Extrahepatic Drug Metabolism and Chemical Carcinogenesis (Rydström J, Montelius J, Bengtsson M, eds), pp 379-388, Elsevier/North-Holland Biomedical Press, Amsterdam
232. Legraverend C, Harrison DE, Ruscetti FW, Nebert DW, 1983, Bone marrow toxicity induced by oral benzo[a]pyrene: Protection resides at the level of the intestine and liver. In: Extrahepatic Drug Metabolism and Chemical Carcinogenesis (Rydström J, Montelius J, Bengtsson M, eds), pp 423-424, Elsevier/North-Holland Biomedical Press, Amsterdam
233. Kärenlampi SO, Legraverend C, Lalley PA, Kozak CA, Nebert DW, 1983, Assignment of the Ah locus to mouse chromosome 17. In: Extrahepatic Drug Metabolism and Chemical Carcinogenesis (Rydström J, Montelius J, Bengtsson M, eds), pp 425-426, Elsevier/North-Holland Biomedical Press, Amsterdam
234. Legraverend C, Harrison DE, Ruscetti FW, Nebert DW, 1983, Bone marrow toxicity induced by oral benzo[a]pyrene: Protection resides at the level of the intestine and liver. Toxicol Appl Pharmacol 70, 390-401
235. Lubet RA, Connolly G, Kouri RE, Nebert DW, Bigelow SW, 1983, Biological effects of the Sudan dyes: Role of the Ah cytosolic receptor. Biochem Pharmacol 32, 3053-3058
236. Fysh JM, Andrews LS, Nebert DW, 1983, Androgen receptor-mediated genetic differences in 2-acetylaminofluorene and dimethylnitrosamine mutagenesis in vitro. Anticancer Res 3, 305-310
237. Nebert DW, Tukey RH, Eisen HJ, Negishi M, 1983, Cloned cytochrome P-450 genes regulated by the Ah receptor. In: Gene Expression: UCLA Symposia on Molecular and Cellular Biology, New Series vol 8 (Hamer D, Rosenberg M, eds), Part 3, pp 187-206, Alan R Liss, Inc, New York
238. Nebert DW, 1983, Impact of genetics and genetic monitoring on pharmacology studies. In: Biomedical Research: Importance of Laboratory Animal Genetics, Health, and Environment, pp 125-156, Charles River Laboratories Press, Massachusetts
239. Kouri RE, Connolly GM, Nebert DW, Lubet RA, 1983, Association between susceptibility to dibenzanthracene- induced fibrosarcoma formation and the Ah locus. Int J Cancer 32, 765-768
240. Kouri RE, Lubet RA, McKinney CE, Connolly GM, Nebert DW, McLemore TL, 1983, Aryl hydrocarbon hydroxylase activity “of mice and humans.” In: Application of Biological Markers to Carcinogen Testing (Milman HA, Sell S, eds), pp 179-197, Plenum Publishing Corporation, New York
241. Lazarte RA, Bigelow SW, Nebert DW, Levitt RC, 1984, Effects of cimetidine on theophylline, acetaminophen, and zoxazolamine toxicity in the intact mouse. Dev Pharmacol Ther 7, 21-29
242. Levine AS, McKinney CE, Echelberger CK, Kouri RE, Edwards BK, Nebert DW, 1984, Aryl hydrocarbon hydroxylase inducibility among primary relatives of children with leukemia or solid tumors. Cancer Res 44, 358-362
243. Nebert DW, Negishi M, 1984, Environmental and genetic factors influencing drug metabolism and toxicity. In: Drug Metabolism and Drug Toxicity (Mitchell JR, Horning MG, eds), pp 137-161, Raven Press, New York
244. Nebert DW, Nakamura M, Tukey RH, Negishi M, 1984, Cloning genes that encode enzymes which metabolize drugs and chemical carcinogens. In: Biochemical Basis of Chemical Carcinogenesis (Greim H, Jung R, Kramer M, Marquardt H, Oesch F, eds), pp 89-105, Raven Press, New York
245. Nebert DW, Negishi M, Chen YT, Tukey RH, 1984, Cloning genes that encode inducible forms of P-450. Biochem Soc Transact 12, 99-101
246. Legraverend C, Guenthner TM, Nebert DW, 1984, Importance of the route of administration for genetic differences in benzo[a]pyrene-induced in utero toxicity and teratogenicity. Teratology 29, 35-47
247. Ohyama T, Nebert DW, Negishi M, 1984, Isosafrole-induced cytochrome P2-450 in DBA/2N mouse liver: Characterization and genetic control of induction. J Biol Chem 259, 2675-2682
248. Stupans I, Ikeda T, Kessler DJ, Nebert DW, 1984, Characterization of a cDNA clone for mouse phenobarbital- inducible cytochrome P-450b. DNA 3, 129-138
249. Kimura S, Gonzalez FJ, Nebert DW, 1984, Mouse cytochrome P3-450: Complete cDNA and amino acid sequence.
Nucleic Acids Res 12, 2917-2928
250. Nebert DW, Eisen HJ, Hankinson O, 1984, The Ah receptor: Binding specificity only for foreign chemicals?
Biochem Pharmacol 33, 917-924
251. Nebert DW, Brown DD, Towne DW, Eisen HJ, 1984, Association of fertility, fitness and longevity with the murine
Ah locus among (C57BL/6N)(C3H/HeN) recombinant inbred lines. Biol Reprod 30, 363-373
252. Rispin AS, Kon H, Nebert DW, 1984, Changes in cytochrome P-450 iron spin state as a function of castration,
testosterone or estrogen treatment, vigorous exercise, or starvation. Biochem Pharmacol 33, 1619-1624
253. Tukey RH, Lalley PA, Nebert DW, 1984, Localization of cytochrome P1-450 and P3-450 genes to mouse chromosome
9. Proc Natl Acad Sci USA 81, 3163-3166
254. Eisen HJ, Nebert DW, 1984, Genetic regulation of mammalian P-450 induction. In: Molecular and Cellular Approaches to Understanding Mechanisms of Toxicity (Tashjian AH Jr, ed), pp 14-27, Harvard School of Public Health, Boston, Massachusetts
255. Legraverend C, Kärenlampi SO, Bigelow SW, Lalley PA, Kozak CA, Womack JE, Nebert DW, 1984, Aryl hydrocarbon hydroxylase induction by benzo[a]anthracene: Regulatory gene localized to the distal portion of mouse chromosome 17. Genetics 107, 447-461
256. Lovell DP, Totman P, Bigelow SW, Nebert DW, Hoffman HA, Greig JB, Festing MFW, 1984, An investigation of genetic variation within a series of congenic strains of mice. Lab Animals 18, 291-297
257. Gonzalez FJ, Tukey RH, Nebert DW, 1984, Structural gene products of the Ah locus. Transcriptional regulation of cytochrome P1-450 and P3-450 mRNA levels by 3-methylcholanthrene. Mol Pharmacol 26, 117-121
258. Kouri RE, Levine AS, Edwards BK, McLemore TL, Vesell ES, Nebert DW, 1984, Source of interindividual variations in aryl hydrocarbon hydroxylase in mitogen-activated human lymphocytes. In: Genetic Variability in Responses to Chemical Exposure: Banbury Report No. 16 (Omenn GS, Gelboin HV, eds), pp 131-144, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
259. Gonzalez FJ, Mackenzie PI, Kimura S, Nebert DW, 1984, Isolation and characterization of mouse full-length cDNA and genomic clones of 3-methylcholanthrene-inducible cytochrome P1-450 and P3-450. Gene 29, 281-292
260. Kouri RE, McKinney CE, Levine AS, Edwards BK, Vesell ES, Nebert DW, McLemore TL, 1984, Variations in aryl hydrocarbon hydroxylase activities in mitogen-activated human and nonhuman primate lymphocytes. Toxicol Pathol 12, 44-48
261. Kimura S, Gonzalez FJ, Nebert DW, 1984, The murine Ah locus. Comparison of the complete cytochrome P1-450 and P3-450 cDNA nucleotide and amino acid sequences. J Biol Chem 259, 10705-10713
262. Kaipainen P, Nebert DW, Lang MA, 1984, Purification and characterization of a microsomal cytochrome P-450 with high activity of coumarin 7-hydroxylase from mouse liver. Eur J Biochem 144, 425-431
263. Lubet RA, Brunda MB, Taramelli D, Dansie D, Nebert DW, Kouri RE, 1984, Induction of immunotoxicity by polycyclic hydrocarbons: Role of the Ah locus. Arch Toxicol 56, 18-24
264. Tukey RH, Nebert DW, 1984, Regulation of mouse cytochrome P3-450 by the Ah receptor. Studies with a P3-450 cDNA clone. Biochemistry 23, 6003-6008
265. Nebert DW, Kimura S, Gonzalez FJ, 1984, Cytochrome P-450 genes and their regulation. In: Molecular Biology of Development (Davidson EH, Firtel RA, eds), pp 309-329, Alan R Liss, Inc, New York
266. Hankinson O, Andersen RD, Birren B, Sander F, Negishi M, Nebert DW, 1985, Mutations affecting the regulation of transcription of the cytochrome P1-450 gene in the mouse Hepa-1 cell line. J Biol Chem 260, 1790-1795

267. Nebert DW, Gonzalez FJ, 1985, Cytochrome P-450 gene expression and regulation. Trends Pharmacol Sci 6, 160- 164
268. Hildebrand CE, Gonzalez FJ, McBride OW, Nebert DW, 1985, Assignment of the human 2,3,7.8-tetrachlorodibenzo- p-dioxin-inducible cytochrome P1-450 gene to chromosome 15. Nucleic Acids Res 13, 2009-2016
269. Jaiswal AK, Gonzalez FJ, Nebert DW, 1985, Human dioxin-inducible cytochrome P1-450: Complementary DNA and amino acid sequence. Science 228, 80-83
270. Nebert DW, 1985, P450 genes and their regulation. Trends Pharmacol Sci [Meeting Report] 6, 270-273
271. Gonzalez FJ, Kimura S, Nebert DW, 1985, Comparison of the flanking regions and introns of the mouse 2,3,7,8-
tetrachlorodibenzo-p-dioxin-inducible cytochrome P1-450 and P3-450 genes. J Biol Chem 260, 5040-5049
272. Bigelow SW, Zijlstra JA, Vögel EW, Nebert DW, 1985, Measurements of the cytosolic Ah receptor among four
strains of Drosophila melanogaster. Arch Toxicol 56, 219-225
273. Nebert DW, Kimura S, Gonzalez FJ, 1985, Molecular mechanisms of P-450 gene expression following exposure to foreign drugs and carcinogens. In: Microsomes and Drug Oxidations (Boobis AR, Caldwell J, DeMatteis F, Elcombe CR, eds), pp 145-156, Taylor and Francis Ltd, London, England
274. Van Cantfort J, Gielen JE, Nebert DW, 1985, Benzo[a]pyrene metabolism in mouse liver. Association of both 7,8- epoxidation and covalent binding of a metabolite of the 7,8-diol with the Ah locus. Biochem Pharmacol 34, 1821- 1826
275. Gonzalez FJ, Nebert DW, Hardwick JP, Kasper CB, 1985, Complete cDNA and protein sequence of a pregnenolone- 16α-carbonitrile-induced cytochrome P-450. A representative of a new gene family. J Biol Chem 260, 7435-7441
276. Jaiswal AK, Gonzalez FJ, Nebert DW. Human P1-450 gene sequence and correlation of mRNA with genetic differences in benzo[a]pyrene metabolism. Nucleic Acids Res 1985; 13: 4503-4520
277. Jaiswal AK, Nebert DW, Eisen HJ, 1985, Comparison of aryl hydrocarbon hydroxylase and acetanilide 4-hydroxylase induction by polycyclic aromatic compounds in human and mouse cell lines. Biochem Pharmacol 34, 2721-2731
278. Hildebrand CE, Gonzalez FJ, Kozak CA, Nebert DW, 1985, Regional linkage analysis of the dioxin-inducible P-450 gene family on mouse chromosome 9. Biochem Biophys Res Commun 130, 396-406
279. Hildebrand CE, Stallings RL, Gonzalez FJ, Nebert DW, 1985, Assignment of dioxin-inducible cytochrome P-450 gene family to Chinese hamster chromosome 4. Somat Cell Mol Genet 11, 391-395
280. Nebert DW, 1985, The Ah locus: Receptor-mediated induction of several drug-metabolizing enzymes by polycyclic hydrocarbons. In: Proceedings of the Ninth European Drug Metabolism Workshop (Siest G, ed), pp 85-92, Pergamon Press, Oxford, England
281. Shichi H, Nebert DW, 1985, Genetic differences in drug metabolism associated with ocular toxicity. In: Toxicology of the Eye, Ear, and Other Special Senses - Target Organ Toxicology Series (Hayes AW, ed), pp 213-229, Raven Press, New York
282. Tuteja N, Gonzalez FJ, Nebert DW, 1985, Developmental and tissue-specific differential regulation of the mouse dioxin-inducible P1-450 and P3-450 genes. Dev Biol 112, 177-184
283. Kimura S, Nebert DW, 1985, Comparison of the mouse P1450 gene and flanking sequences from a MOPC 41 plasmacytoma and normal liver. DNA 4, 365-375
284. Gonzalez FJ, Nebert DW, 1985, Autoregulation plus upstream positive and negative control regions associated with transcriptional activation of the mouse P1450 gene. Nucleic Acids Res 13, 7269-7288
285. Bigelow SW, Nebert DW, 1986, The murine aromatic hydrocarbon responsiveness locus: A comparison of receptor levels and several inducible enzyme activities among recombinant inbred lines. J Biochem Toxicol 1, 1-14
286. Tuteja N, Gonzalez FJ, Nebert DW, 1986, An example of P450 catalytic activities not correlated with corresponding
P-450 mRNA concentrations. Biochem Pharmacol 35, 718-720
287. Kimura S, Gonzalez FJ, Nebert DW, 1986, Tissue-specific expression of the mouse dioxin-inducible P1450 and P3450 genes: Differential transcriptional activation and mRNA stability in liver and extrahepatic tissues. Mol Cell Biol 6, 1471-1477
288. Chen YT, Nebert DW, 1986, Recombinant DNA approaches to human pharmacogenetic disorders. In: Genes and Disease (Wu M, Nebert DW, eds), pp 59-79, Science Press, Beijing, China
289. Kouri RE, McLemore TL, Jaiswal AK, Nebert DW, 1986, Current cellular assays for measuring clinical drug metabolizing capacity--Impact of new molecular biologic techniques. In: Ethnic Differences in Reactions to Drugs and Xenobiotics (Kalow W, Goedde HW, Agarwal DP, eds), pp 453-469, Alan R Liss, Inc, New York
290. Jaiswal AK, Nebert DW, 1986, Two RFLPs associated with the human P1450 gene linked to the MPI locus on chromosome 15. Nucleic Acids Res 14, 4376
291. Peterson TC, Gonzalez FJ, Nebert DW, 1986, Methylation differences in the murine P1-450 and P3-450 genes in wild- type and mutant hepatoma cell cultures. Biochem Pharmacol 35, 2107-2114
292. Kimura S, Nebert DW, 1986, cDNA and complete amino acid sequence of mouse P2450: Allelic variant of the mouse P3450 gene. Nucleic Acids Res 14, 6765-6766
293. Jaiswal AK, Nebert DW, Gonzalez FJ, 1986, Human P3450: cDNA and complete amino acid sequence. Nucleic Acids Res 14, 6773-6774
294. Neuhold LA, Gonzalez FJ, Jaiswal AK, Nebert DW, 1986, Dioxin-inducible enhancer region upstream from the mouse P1450 gene and interaction with a heterologous SV40 promoter. DNA 5, 403-411
295. Robertson JA, Chen HC, Nebert DW, 1986, NAD(P)H:menadione oxidoreductase: Novel purification of enzyme, cDNA and complete amino acid sequence, and gene regulation. J Biol Chem 261, 15794-15799
296. Gonzalez FJ, Jaiswal AK, Nebert DW, 1986, P450 genes: Evolution, regulation and relationship to human cancer. In: Cold Spring Harbor Symposia on Quantitative Biology: Molecular Biology of Homo sapiens, vol 51, pp 879-890, Cold Spring Harbor Laboratory, New York
297. Nebert DW, Adesnik M, Coon MJ, Estabrook RW, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Kemper B, Levin W, Phillips IR, Sato R, Waterman MR, 1987, The P450 gene superfamily. Recommended nomenclature. DNA 6, 1-11
298. Nebert DW, Gonzalez FJ, 1987, P450 genes and evolutionary genetics. Hosp Practice 22, 63-74
299. Jaiswal AK, Nebert DW, McBride OW, Gonzalez FJ, 1987, Human P3450: cDNA and complete protein sequence, repetitive Alu sequences in the 3' nontranslated region, and localization of gene to chromosome 15. J Exp Pathol 3, 1- 17
300. Kimura S, Donovan JC, Nebert DW, 1987, Expression of the mouse P1450 gene during differentiation without foreign chemical stimulation. J Exp Pathol 3, 61-74
301. Krasnewich D, Kozak CA, Nebert DW, Mackenzie PI, 1987, Localization of UDP glucuronosyltransferase gene(s) on mouse chromosome 5. Somat Cell Mol Genet 13, 179-182
302. Gonzalez FJ, Matsunaga T, Nagata K, Meyer U, Nebert DW, Pastewka J, Kozak CA, Gillette JR, Gelboin HV, Hardwick JP, 1987, Debrisoquine 4-hydroxylase: Characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism. DNA 6, 149-161
303. Bale AE, Nebert DW, McBride OW, 1987, Subchromosomal localization of the dioxin-inducible P1450 locus (CYP1) and description of two RFLPs detected with a 3' P1450 cDNA probe. Cytogenet Cell Genet 46, 574-575
304. Jaiswal AK, Gonzalez FJ, Nebert DW, 1987, Comparison of human and mouse P1450 upstream regulatory sequences in liver- and nonliver-derived cell lines. Mol Endocrinol 1, 312-320
305. Nebert DW, Gonzalez FJ, 1987, P450 genes: Structure, evolution and regulation. Annu Rev Biochem 56, 945-993
306. Kimura S, Smith HH, Hankinson O, Nebert DW, 1987, Analysis of two benzo[a]pyrene-resistant mutants of the mouse hepatoma Hepa-1 P1450 gene via cDNA expression in yeast. EMBO J 6, 1929-1933
307. Nebert DW, Jaiswal AK, 1987, Human drug metabolism polymorphisms: Use of recombinant DNA techniques. Pharmac Ther 33, 11-17
308. Nebert DW, Jaiswal AK, Meyer UA, Gonzalez FJ, 1987, Human P-450 genes: Evolution, regulation and possible role in carcinogenesis. Biochem Soc Transact 15, 586-589
309. Robertson JA, Hankinson O, Nebert DW, 1987, Autoregulation plus positive and negative elements controlling transcription of genes in the [Ah] battery. Chem Scripta 27A, 83-87
310. Yang FD, Ling LW, Wu DF, Yang CP, Liang JG, Chen WZ, Wang P, Zhang C, Xue ES, Du HL, Gao SD, Ye Z, Sun CS, Nebert DW, 1987, The influence of cigarette smoke on the carcinogenic effect of AFB1 in ducks. Short-term observation [in Chinese]. Chin J Clin Oncol 14, 250-252
311. Robertson JA, Nebert DW, 1987, cDNA and complete amino acid sequence of rat 3-methylcholanthrene-inducible NAD(P)H:menadione oxidoreductase. In: Drug Metabolism - From Molecules To Man (Benford DJ, Bridges JW, Gibson GG, eds), pp 297-299, Taylor & Francis, Inc, London
312. Jaiswal AK, Neuhold LA, Nebert DW, 1987, Human P450IA1 upstream regulatory sequences expressing the chloramphenicol acetyltransferase gene. Effect of Ha-MSV enhancer and comparison of transient with stable transformation assays. Biochem Biophys Res Commun 148, 857-863
313. Nebert DW, 1987, P450 genes: Nomenclature and molecular biology. In: Cytochrome P-450: New Trends (Sato R, Omura T, Imai Y, Fujii-Kuriyama Y, eds), pp 89-92, Yamada Science Foundation, Japan
314. Nebert DW, 1988, Genes encoding drug-metabolizing enzymes: Possible role in human disease. In: Phenotypic Variation in Populations (Woodhead AD, Bender MA, Leonard RC, eds), pp 45-64, Plenum Publishing Corporation, New York
315. Nebert DW, 1988, The 1986 Bernard B. Brodie Award Lecture: The genetic regulation of drug-metabolizing enzymes. Drug Metab Dispos 16, 1-8
316. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA, 1988, Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331, 442-446
317. Nebert DW, Jones JE, Owens J, Puga A, 1988, Evolution of the P450 gene superfamily. In: Oxidases and Related Redox Systems (King TE, Mason HS, Morrison M, eds), Progr Clin Biol Res 274, 557-576, Alan R Liss, Inc, New York
318. Gonzalez FJ, Vilbois F, Hardwick JP, McBride OW, Nebert DW, Gelboin HV, Meyer UA, 1988, Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and mapping of the CYP2D locus to chromosome 22. Genomics 2, 174-179
319. Gonzalez FJ, Skoda R, Hardwick JP, Song BJ, Umeno M, McBride OW, Kozak CA, Matsunaga E, Matsunaga T, Kimura S, Park SS, Yang CS, Nebert DW, Gelboin HV, Meyer UA, 1988, Human and rat debrisoquine 4-hydroxylase and ethanol-inducible P450 gene families: Structure, regulation and polymorphisms. In: Microsomes and Drug Oxidations (Miners J, Birkett DJ, Drew R, McManus M, eds), pp 209-215, Taylor & Francis Ltd, London
320. Heilmann LJ, Sheen YY, Bigelow SW, Nebert DW, 1988, The trout P450IA1. cDNA and deduced protein sequence, expression in liver, and evolutionary significance. DNA 7, 379-387
321. Jaiswal AK, McBride OW, Adesnik M, Nebert DW, 1988, Human dioxin-inducible cytosolic NAD(P)H:menadione oxidoreductase: cDNA sequence and localization of gene to chromosome 16. J Biol Chem 263, 13572-13578

322. Nebert DW, Gonzalez FJ, 1988, The human P450 gene superfamily and its relationship to malignancy and toxicity. In: Syllabus for the American Association for the Study of Liver Diseases (AASLD), pp 171-178, AASLD Press, Chicago, Illinois
323. Ivy SP, Tulpule A, Fairchild CR, Averbuch SD, Myers CE, Nebert DW, Baird WM, Cowan KH, 1988, Altered regulation of P450IA1 expression in a multidrug-resistant MCF-7 human breast cancer cell line. J Biol Chem 263, 19119-19125
324. Nebert DW, Nelson DR, Adesnik M, Coon MJ, Estabrook RW, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Kemper B, Levin W, Phillips IR, Sato R, Waterman MR, 1989, The P450 gene superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA 8, 1-13
325. Feyereisen R, Koener JF, Farnsworth DE, Nebert DW, 1989, Isolation and sequence of cDNA encoding a cytochrome P450 from an insecticide-resistant strain of the house fly, Musca domestica. Proc Natl Acad Sci USA 86, 1465-1469
326. Nebert DW, Jones JE, 1989, Regulation of the mammalian cytochrome P1450 (CYP1A1) gene. Int J Biochem 21, 243-252
327. Nebert DW, 1989, Regulation of the mouse dioxin-inducible P1450 gene. In: The Biochemistry and Biophysics of Cytochrome P-450 (Schuster I, ed), pp 484-490, Taylor & Francis Ltd, London
328. Gonzalez FJ, Kimura S, Matsunaga E, Umeno M, Aoyama T, Skoda R, Vilbois F, Hardwick JP, Nebert DW, Gelboin HV, Meyer UA, 1989, Structure and evolution of the rat and human debrisoquine 4-hydroxylase (P450IID) gene family. In: The Biochemistry and Biophysics of Cytochrome P-450 (Schuster I, ed), pp 564-567, Taylor & Francis Ltd, London
329. Neuhold LA, Shirayoshi Y, Ozato K, Jones JE, Nebert DW, 1989, Regulation of mouse Cyp1a1 gene expression by dioxin. Requirement of two cis-acting elements during the induction process. Mol Cell Biol 9, 2378-2386
330. Jones JE, Nebert DW, 1989, Transcriptional start site in the mouse Cyp1a1 (cytochrome P1450) gene. DNA 8, 527- 534
331. Petersen DD, Gonzalez FJ, Rapic V, Kozak CA, Lee JY, Jones JE, Nebert DW, 1989, Marked increases in hepatic NAD(P)H:menadione oxidoreductase gene transcription and mRNA levels correlated with a mouse chromosome 7 deletion. Proc Natl Acad Sci USA 86, 6699-6703
332. Fornace AJ Jr, Nebert DW, Hollander MC, Luethy JD, Papathanasiou M, Fargnoli J, Holbrook NJ, 1989, Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol Cell Biol 9, 4196-4203
333. Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, Kimura S. Human CYP1A2. Sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol Endocrinol 1989; 3: 1399-1408
334. Nebert DW, Nelson DR, Feyereisen R, 1989, Evolution of the cytochrome P450 genes. Xenobiotica 19, 1149-1160
335. Bigelow SW, Collins AC, Nebert DW, 1989, Selective mouse breeding for short ethanol sleep time has led to high
levels of the hepatic aromatic hydrocarbon (Ah) receptor. Biochem Pharmacol 38, 3565-3572
336. Dey A, Westphal H, Nebert DW, 1989, Cell type-specific expression of mouse inducible CYP1A1 mRNA during
development. Proc Natl Acad Sci USA 86, 7446-7450
337. Nebert DW, Gonzalez FJ, 1989, Cytochrome P450 nomenclature. Drug Metab NewsLetter, vol 19, no 4, pp 2-3
338. Nebert DW. The Ah locus: Genetic differences in toxicity, cancer, mutation and birth defects. Crit Rev Toxicol 1989; 20: 153-174
339. Puga A, Nebert DW, 1990, Evolution of the P450 gene superfamily and regulation of the murine Cyp1a1 gene. Biochem Soc Transact 18, 7-10
340. Nebert DW, Weber WW, 1990, Pharmacogenetics. In: Principles of Drug Action. The Basis of Pharmacology, 3rd ed (Pratt WB, Taylor PW, eds), pp 469-531, Churchill Livingstone Inc, New York
341. Gonzalez FJ, Nebert DW, 1990, Evolution of the P450 gene superfamily: Animal-plant “warfare,” molecular drive,
and human genetic differences in drug oxidation. Trends Genet 6, 182-186
342. Puga A, RayChaudhuri B, Salata K, Zhang YH, Nebert DW, 1990, Stable expression of mouse Cyp1a1 and human CYP1A2 cDNAs transfected into mouse hepatoma cells lacking detectable P450 enzyme activity. DNA Cell Biol 9, 425-436
343. Nebert DW, Petersen DD, Fornace AJ Jr, 1990, Cellular responses to oxidative stress. In: Biological Oxidation Systems (Reddy CC, Hamilton GA, Madyastha KM, eds), pp 69-84, Academic Press, Inc, New York
344. Nebert DW, Petersen DD, Fornace AJ Jr, 1990, Cellular responses to oxidative stress: The [Ah] gene battery as a paradigm. Environ Health Perspect 88, 13-25
345. Nebert DW, 1990, Growth signal pathways. Nature 347, 709-710
346. Owens RA, Nebert DW, 1990, Expression of the chloramphenicol acetyltransferase (CAT) reporter gene by the murine Cyp1a-2 (cytochrome P3450) promoter in hepatoma cell cultures. Biochem Biophys Res Commun 172, 1109- 1115
347. RayChaudhuri B, Nebert DW, Puga A, 1990, The Cyp1a1 gene negatively regulates its own transcription and that of other members of the aromatic hydrocarbon-responsive [Ah] gene battery. Mol Endocrinol 4, 1773-1781
348. Gonzalez FJ, Liu SY, Kozak CA, Nebert DW, 1990, Decreased Hnf-1 gene expression in mice homozygous for a 1.2- centiMorgan deletion on chromosome 7. DNA Cell Biol 9, 771-776
349. Nebert DW, Gonzalez FJ, 1990, The P450 gene superfamily. In: Frontiers in Biotransformation. Principles, Mechanisms and Biological Consequences of Induction, (Rückpaul K, Rein H, eds), vol 2, Akademie-Verlag Berlin, pp 35-61
350. Nebert DW, Nelson DR, Coon MJ, Estabrook RW, Feyereisen R, Fujii-Kuriyama Y, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Loper JC, Sato R, Waterman MR, Waxman DJ, 1991, The P450 superfamily: Update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol 10, 1-14
351. Shaw PM, Reiss A, Adesnik M, Nebert DW, Schembri J, Jaiswal AK, 1991, The human dioxin-inducible NAD(P)H:quinone reductase cDNA-encoded protein expressed in COS-1 cells is identical to diaphorase 4. Eur J Biochem 195, 171-176
352. Nebert DW, 1991, Role of genetics and drug metabolism in human cancer risk. Mutat Res 247, 267-281 PMID: 2011144
353. Nebert DW, 1991, Polymorphism of human CYP2D gene involved in drug metabolism: Possible relationship to individual cancer risk. Cancer Cells 3, 93-96
354. Petersen DD, McKinney CE, Ikeya K, Smith HH, Bale AE, McBride OW, Nebert DW, 1991, Human CYP1A1 gene: Cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet 48, 720-725 PMID: 1707592
355. Nebert DW, Nelson DR, Coon MJ, Estabrook RW, Feyereisen R, Fujii-Kuriyama Y, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Loper JC, Sato R, Waterman MR, Waxman DJ, 1981, Corrigendum. The P450 superfamily: Update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol 10, 397-398
356. Teeter LD, Petersen DD, Nebert DW, Kuo MT, 1991, Murine mdr-1, mdr-2 and mdr-3 gene expression: No coinduction with the Cyp1a-1 and Nmo-1 genes in liver by 2,3,7,8-tetrachlorodibenzo-p-dioxin. DNA Cell Biol 10, 433-441
357. Nebert DW, 1991, Identification of genetic differences in drug metabolism: Prediction of individual risk of toxicity or cancer. Hepatology 14, 398-401
358. Burchell B, Nebert DW, Nelson DR, Bock KW, Iyanagi T, Jansen PLM, Lancet D, Mulder GJ, Roy Chowdhury J, Siest G, Tephly TR, Mackenzie PI, 1991, The UDP glucuronosyltransferase gene superfamily: Suggested nomenclature based on evolutionary divergence. DNA Cell Biol 10, 487-494

359. Haque SJ, Mackenzie PI, Petersen DD, Nebert DW, 1991, Isolation, sequence, and developmental expression of rat UGT2B2: gene encoding a constitutive UDP glucuronosyl-transferase that metabolizes etiocholanolone and androsterone. DNA Cell Biol 10, 515-524
360. Dey A, Nebert DW, Ozato K, 1991, The cyclic AMP- and serum-response elements and the AP-1 site of the c-fos gene are constitutively occupied in vivo. DNA Cell Biol 10, 537-544
361. Tefré T, Ryberg D, Haugen A, Nebert DW, Skaug V, Brügger A, Bürresen, AL, 1991, Human CYP1A1 (cytochrome P1450) gene: Lack of association between the Msp I RFLP and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1, 20-25
362. Rapic V, Nebert DW, 1991, Analysis of constitutive and TCDD-inducible expression of genes in the [Ah] battery. In: Anticarcinogenesis and Radiation Protection II (Nygaard OF, Upton AC, eds), pp 93-98, Plenum Press, New York
363. Nebert DW. Proposed role of drug-metabolizing enzymes: Regulation of steady state levels of the ligands that effect growth, homeostasis, differentiation, and neuroendocrine functions. Mol Endocrinol 1991; 5: 1203-1214
364. Nebert DW, Petersen DD, Puga A, 1991, Human AH locus polymorphism and cancer: Inducibility of CYP1A1 and other genes by combustion products and dioxin. Pharmacogenetics 1, 68-78
365. Lin LW, Yang FD, Ye Z, Xu E, Yang CP, Zhang C, Wu DF, Nebert DW, 1991, Case-control study of cigarette smoking and primary hepatoma in an aflatoxin-endemic region of China: A protective effect. Pharmacogenetics 1, 79-85
366. Nebert DW, Nelson DR, 1991, P450 gene nomenclature based on evolution. Methods Enzymol, Cytochrome P450 (Waterman MR, Johnson EF, eds), vol 206, pp 3-11, Academic Press, Orlando, Florida
367. Petersen DD, Kong AN, Jorge LF, Nebert DW, Arias TD, 1991, Debrisoquine polymorphism: Novel CYP2D6 gene Bam HI RFLP in the Ngawbé Guaymí Indian of Panama. Pharmacogenetics 1, 136-142 PMID: 1688244
368. Puga A, RayChaudhuri B, Nebert DW, 1992, Transcriptional derepression of the murine Cyp1a1 gene by mevinolin. FASEB J 6, 777-785
369. Nebert DW, 1992, Identification of genetic differences in debrisoquine hydroxylase activity. Reply. Hepatology 15, 360
370. Liang HC, Shertzer HG, Nebert DW, 1992, “Oxidative stress” response in liver of an untreated newborn mouse having a 1.2-centiMorgan deletion on chromosome 7. Biochem Biophys Res Commun 182, 1160-1165
371. Wu KH, Yang FD, Nebert DW, 1992, Effect of tobacco smoke on DNA content of aflatoxin B1-induced precancerous cells in mouse liver. Chin J Clin Oncol 19, 394-398
372. Carrier F, Owens RA, Nebert DW, Puga A, 1992, Dioxin-dependent activation of murine Cyp1a-1 gene transcription requires protein kinase C-dependent phosphorylation. Mol Cell Biol 12, 1856-1863
373. Puga A, Nebert DW, Carrier F, 1992, Dioxin induces expression of c-fos and c-jun proto-oncogenes and a large increase in transcriptional factor AP-1. DNA Cell Biol 11, 269-281
374. Vasiliou V, Puga A, Nebert DW, 1992, Negative regulation of the murine cytosolic aldehyde dehydrogenase-3 (Aldh- 3c) gene by functional CYP1A1 and CYP1A2 proteins. Biochem Biophys Res Commun 187, 413-419
375. Nebert DW, 1992, Proposed role of drug-metabolizing enzymes in signal transduction pathways. In: Cytochrome P450: Biochemistry and Biophysics (Archakov AI, Bachmanova GI, eds), pp 358-363, INCO-TNC Joint Stock Company, Moscow
376. Carrier F, Owens RA, Neuhold LA, Nebert DW, Puga A, 1992, Activation of the murine Cyp1a-1 (cytochrome P1450) gene requires protein phosphorylation: Possible involvement of protein kinase C. In: Cytochrome P450: Biochemistry and Biophysics (Archakov AI, Bachmanova GI, eds), pp 449-451, INCO-TNC Joint Stock Company, Moscow
377. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, Okuda K, Nebert DW, 1993, The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names, and nomenclature. DNA Cell Biol 12, 1-51
378. Vasiliou V, Puga A, Nebert DW, 1993, Mouse class 3 aldehyde dehydrogenases: Positive and negative regulation of gene expression. Advanc Exp Med Biol 328, 131-139
379. Nebert DW, Puga A, Vasiliou V, 1993, Role of the Ah receptor and the dioxin-inducible [Ah] gene battery in toxicity, cancer and in signal transduction. Ann N Y Acad Sci 685, 624-640
380. Liu RM, Nebert DW, Shertzer HG, 1993, Menadione toxicity in two mouse liver established cell lines having striking genetic differences in quinone reductase activity and glutathione concentrations. Toxicol Appl Pharmacol 122, 101- 107
381. Jorge LF, Arias TD, Griese U, Nebert DW, Eichelbaum M, 1993, Evolutionary pharmacogenetics of CYP2D6 in Ngawbé Guaymí of Panama: Allele-specific PCR detection of the B allele and RFLP analysis. Pharmacogenetics 3, 231-238
382. Pilon AL, Kozak CA, Nebert DW, Puga A, 1993, Localization of the murine Hmg1 gene, encoding an HMG box protein, to mouse chromosome 2. Mamm Genome 4, 612-614
383. Nebert DW, 1993, Elevated estrogen 16α-hydroxylase activity: Is this a “genotoxic” or “nongenotoxic” biomarker in human breast cancer risk? J Natl Cancer Inst 85, 1888-1891
384. Vasiliou V, Reuter SF, Kozak CA, Nebert DW, 1993, Mouse dioxin-inducible cytosolic aldehyde dehydrogenase-3: AHD4 cDNA sequence, genetic mapping, and differences in mRNA levels. Pharmacogenetics 3, 281-290
385. Chang CY, Smith DR, Prasad VS, Sidman CL, Nebert DW, Puga A, 1993, Ten nucleotide differences, five of which cause amino acid changes, are associated with the Ah receptor locus polymorphism of C57BL/6 and DBA/2 mice. Pharmacogenetics 3, 312-321
386. Nebert DW, 1994, Drug-metabolizing enzymes in ligand-modulated transcription. Biochem Pharmacol 47, 25-37
387. Wedlund PJ, Kimura S, Gonzalez FJ, Nebert DW, 1994, I462V mutation in the human CYP1A1 gene: Lack of correlation with either the Msp I (M2) allele or CYP1A1 inducibility in a 3-generation family of East Mediterranean descent. Pharmacogenetics 4, 21-26
388. Nebert DW, 1994, Drug metabolism and signal transduction: Possible role of Ah receptor and arachidonic acid cascade in protection from ethanol toxicity. In: Toward a Molecular Basis of Alcohol Use and Abuse (Jansson B, Jörnvall H, Rydberg U, Terenius L, Vallee B, eds), pp 231-240, Nobel Symposium Press, Stockholm
389. Nebert DW, 1994, Breaking the code of environmental genetics. Environ Health Perspect 102, 432-435
390. Nebert DW, Feyereisen R, 1994, Evolutionary argument for a connection between drug metabolism and signal transduction. In: Cytochrome P450: Biochemistry, Biophysics and Molecular Biology (Lechner MC, ed), pp 3-13, John Libbey Eurotext Ltd, London
391. Pappas P, Vasiliou V, Nebert DW, Marselos M, 1994, Lack of response of the rat liver “Class 3" cytosolic aldehyde dehydrogenase activity to toxic chemicals, glutathione depletion, and other forms of stress. Biochem Pharmacol 48, 841-845
392. Nebert DW, McKinnon RA, 1994, Cytochrome P450: evolution and functional diversity. Progr Liv Dis 12, 63-97
393. Liu RM, Vasiliou V, Zhu H, Duh JL, Tabor MW, Puga A, Nebert DW, Sainsbury M, Shertzer HG, 1994, Regulation of [Ah] gene battery enzymes and glutathione levels by 5,10-dihydroindeno[1,2-b]indole in mouse hepatoma cell lines. Carcinogenesis 15, 2347-2352
394. Carrier F, Chang CY, Duh JL, Nebert DW, Puga, A, 1994, Interaction of the regulatory domains of the murine Cyp1a1 gene with two DNA-binding proteins in addition to the Ah receptor and the Ah receptor nuclear translocator (ARNT). Biochem Pharmacol 48, 1767-1778
395. Vasiliou V, Theurer MJ, Puga A, Reuter SF, Nebert DW, 1994, Mouse dioxin-inducible NAD(P)H:menadione
oxidoreductase: NMO1 cDNA sequence and genetic differences in mRNA levels. Pharmacogenetics 4, 341-348
396. McKinnon RA, Nebert DW, 1994, Possible role of cytochromes P450 in lupus erythematosus and related disorders.
Lupus 3, 473-478
397. Shertzer HG, Vasiliou V, Liu RM, Tabor MW, Nebert DW, 1995, Enzyme induction by L-buthionine (S,R)-
sulfoximine in cultured mouse hepatoma cells. Chem Res Toxicol 8, 431-436
398. Fernandez-Salguero P, Pineau T, Hilbert DM, McPhail T, Lee SST, Kimura S, Nebert DW, Rudikoff S, Ward JM, Gonzalez FJ. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 1995; 268, 722–726
399. Vasiliou V, Reuter SF, Kozak CA, Nebert DW, 1995, Mouse class 3 aldehyde dehydrogenases. Advanc Exp Med Biol 372, 151-158
400. Inaba T, Nebert DW, Burchell B, Bertilsson L, Watkins PB, Goldstein JA, Tucker GT, 1995, Conference summary: Pharmacogenetics, clinical pharmacology and toxicology. Can J Physiol Pharmacol 73, 331-338
401. Vasiliou V, Weiner H, Marselos M, Nebert DW, 1995, Mammalian aldehyde dehydrogenase genes: classification based on evolution, structure and regulation. Eur J Drug Metab Pharmacokin 20, special issue, pp 53-64
402. Vasiliou V, Shertzer HG, Liu RM, Sainsbury M, Nebert DW, 1995, Response of [Ah] battery genes to compounds that protect against menadione toxicity. Biochem Pharmacol 50, 1885-1891
403. Vasiliou V, Puga A, Chang CY, Tabor MW, Nebert DW, 1995, Interaction between the Ah receptor and proteins binding to the AP-1-like electrophile response element (EpRE) during murine Phase II [Ah] battery gene expression. Biochem Pharmacol 50, 2057-2068
404. Karageorgou M, Vasiliou V, Nebert DW, Marselos M, 1995, Ligands of four receptors in the nuclear steroid/thyroid hormone superfamily inhibit induction of rat cytosolic aldehyde dehydrogenase-3 (ALDH-3c) by 3-methylcholan- threne. Biochem Pharmacol 50, 2113-2117
405. Duh JL, Zhu H, Shertzer HG, Nebert DW, Puga, A, 1995, The Y-box motif mediates redox-dependent transcriptional activation in mouse cells. J Biol Chem 270, 30499-30507
406. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. Cytochrome P450 superfamily: Update on new sequences, gene mapping, accession numbers, and nomenclature. Pharmacogenetics 1996; 6: 1–42
407. Liang HCL, Li H, McKinnon RA, Duffy JJ, Potter SS, Puga A, Nebert DW, 1996, Cyp1a2(–/–) null mutant mice develop normally, but show deficient drug metabolism. Proc Natl Acad Sci USA 93, 1671-1676
408. Vasiliou V, Kozak CA, Lindahl R, Nebert DW, 1996, Mouse microsomal Class 3 aldehyde dehydrogenase: AHD3 cDNA sequence, inducibility by dioxin and clofibrate, and genetic mapping. DNA Cell Biol 15, 235-245
409. Nebert DW, McKinnon RA, Puga A, Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 1996; 15, 273-280
410. Puga A, Micka J, Chang CY, Liang HC, Nebert DW, 1996, Role of molecular biology in risk assessment. In: Biological Reactive Intermediates V (Snyder R, Kocsis JJ, Sipes IG, Kalf GF, Jollow DJ, Greim H, Monks TJ, Witmer CM, eds), Advanc Exp Med Biol 387, 395-404, Plenum Press, NY
411. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM, 1996, Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6, 193-201
412. FitzGerald CT, Fernandez-Salguero P, Gonzalez FJ, Nebert DW, Puga A, 1996, Differential regulation of mouse Ah receptor gene expression in cell lines of different tissue origins. Arch Biochem Biophys, 333, 170-178
413. Miller MS, Juchau MR, Guengerich FP, Nebert DW, Raucy JL, 1996, Symposium overview. Drug metabolic enzymes
in developmental toxicology. Fundam Appl Toxicol, 34, 165-175
414. Vasiliou V, Reuter SF, Shiao TY, Puga A, Nebert DW, 1996, Mouse dioxin-inducible Ahd4 gene: structure of the 5'
flanking region and transcriptional regulation. Advanc Exp Med Biol 414, 37-46
415. Nebert DW, Carvan MJ III, 1997, Ecogenetics: from ecology to health. In: Hazardous Waste: Impacts on Human and Ecological Health (Johnson BL, Xintaras C, Andrews JS Jr, eds), pp 85–114, Princeton Scientific Publishing Co., Inc., Princeton NJ
416. Nebert DW, 1997, Polymorphisms in drug-metabolizing enzymes: what is their clinical significance and why do they exist? Am J Hum Genet 1997; 60: 265–271 PMID: 9012398
417. Nebert DW, Duffy JJ, 1997, How knockout mouse lines will be used to study the role of drug-metabolizing enzymes and their receptors during reproduction, development, and environmental toxicity, cancer and oxidative stress. Biochem Pharmacol 53, 249-254
418. Puga A, Nebert DW, McKinnon RA, Menon AG, 1997, Genetic polymorphisms in human drug-metabolizing enzymes: potential uses of reverse genetics to identify genes of toxicological relevance. Crit Rev Toxicol 27, 199-222
419. Micka J, Milatovich A, Menon A, Grabowski GA, Puga A, Nebert DW, Human Ah receptor (AHR) gene: localization to 7p15 and suggestive correlation of polymorphism with CYP1A1 inducibility. Pharmacogenetics 1997; 7: 95–101 PMID: 9170146
420. Vasiliou V, Reuter SF, Nebert DW, 1997, Extrahepatic expression of NAD(P)H:menadione oxidoreductase, UDP glucuronosyltransferase-1A6, microsomal aldehyde dehydrogenase, and hepatic nuclear factor-1" mRNAs in ch/ch and 14CoS/14CoS mice. Biochem Biophys Res Commun 233, 631-636
421. He XX, Nebert DW, Vasiliou V, Zhu H, Shertzer HG, 1997, Genetic differences in alcohol drinking preference between inbred strains of mice. Pharmacogenetics 7, 223-233
422. Nebert DW, Carvan MJ III, 1997, Ecogenetics: from ecology to health. Toxicol Industr Health 13, 163-192
423. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Bélanger A, Fournel-Gigleux S, Green M, Hum DW, Iyanagi T, Lancet D, Louisot P, Magdalou J, Roy Chowdhury J, Ritter JK, Schachter H, Tephly TR, Tipton KF, Nebert DW, 1997, The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7, 255-269
424. Roberts RA, Nebert DW, Hickman JA, Richburg JH, Goldsworthy TL, 1997, Perturbation of the mitosis/apoptosis balance: a fundamental mechanism in toxicology. Fund Appl Toxicol 38, 107-115
425. Liang HC, McKinnon RA, Nebert DW, 1997, Sensitivity of CYP1A1 mRNA inducibility is the same in Cyp1a2(+/+) wild-type and Cyp1a2(-/-) null mutant mice. Biochem Pharmacol 54, 1127-1131
426. Nebert DW, 1997, Book review: Pharmacogenetics by Weber WW. Am J Hum Genet 61, 1461-1462
427. Nebert DW, 1997, Pharmacogenetics: 65 candles on the cake. Pharmacogenetics 7, 435-440
428. Yu M, Jamieson GA Jr, Leikauf GD, Nebert DW, 1998, Phospholipase A2 activation and increases in specific prostaglandins in the oxidatively stressed 14CoS/14CoS mouse hepatocyte line. Biochem Pharmacol 55: 193-200
429. White JA, Maltais LJ, Nebert, DW, 1998, An increasingly urgent need for standardized gene nomenclature. On the Nature Genetics Website at http://www.genetics.nature.com/nomen/nomen_article.html
430. Nebert DW, McKinnon RA, 1998, Genetic determinants of toxic response, In: ILO Encyclopaedia of Occupational Health and Safety (Stellman JM, ed), 4th Edition, International Labour Office, Geneva, Switzerland, pp 33.19-33.26
431. Sinclair PR, Gorman N, Dalton T, Walton HS, Bement WJ, Sinclair JF, Smith AG, Nebert DW, 1998, Uroporphyria produced in mice by iron and 5-aminolevulinic acid does not occur in Cyp1a2(-/-) null mutant mice. Biochem J 330, 149-153

432. White JA, Maltais LJ, Nebert DW, 1998, Networking nomenclature. Nature Genet 18, 209
433. Vorhees CV, Reed TM, Schilling MA, Fisher JE, Moran MS, Cappon GD, Nebert DW, 1998, CYP2D1 polymorphism in methamphetamine-treated rats: genetic differences in neonatal mortality and effects on spatial learning and acoustic startle. Neurotoxicol Teratol 20, 265-273
434. Maier A, Micka J, Miller K, Denko T, Chang CY, Nebert DW, Puga A, 1998, Aromatic hydrocarbon receptor polymorphism: development of new methods to correlate genotype with phenotype. Environ Health Perspect 106, 421-426
435. Gu J, Zhang QY, Genter MB, Lipinskas TW, Negishi M, Nebert DW, Ding X, 1998, Purification and characterization of heterologously expressed mouse CYP2A5 and CYP2G1: role in metabolic activation of acetaminophen and 2,6- dichlorobenzonitrile in mouse olfactory mucosal microsomes. J Pharmacol Exp Ther 285, 1287-1295
436. Genter MB, Liang HC, Gu J, Ding X, Negishi M, McKinnon RA, Nebert DW, 1998, Role of CYP2A5 and 2G1 in acetaminophen metabolism and toxicity in the olfactory mucosa of the Cyp1a2(-/-) mouse. Biochem Pharmacol 55, 1819-1826
437. McKinnon RA, Nebert, 1998, Cytochrome P450 knockout mice: new toxicological models. Clin Exp Pharmacol Physiol 25, 783-787
438. FitzGerald CT, Nebert DW, Puga A, 1998, Regulation of mouse Ah receptor (Ahr) gene expression by members of the Sp family of transcription factors. DNA Cell Biol 17, 811-822
439. McKinnon RA, Nebert DW, 1998, Environmental mutagenesis. In: Environmental and Occupational Medicine (Rom WN, ed), 3rd Edition, Lippincott-Raven Publishers, New York, pp 187-195
440. Dey A, Nebert DW, 1998, Markedly increased constitutive CYP1A1 mRNA levels in the fertilized ovum of the mouse. Biochem Biophys Res Commun 251, 657-661
441. Tonge RP, Kelly EJ, Bruschi SA, Kalhorn T, Eaton DL, Nebert DW, Nelson SD, 1998, Role of CYP1A2 in the hepatotoxicity of acetaminophen: investigations using Cyp1a2 null mice. Toxicol Appl Pharmacol 153, 102-108
442. Shertzer HG, Nebert DW, Puga A, Ary M, Sonntag D, Dixon K, Robinson LJ, Cianciolo E, Dalton TP, 1998, Dioxin causes a sustained oxidative stress response in the mouse. Biochem Biophys Res Commun 253, 44-48
443. DiRocco L, Dalton T, Seyfried TN, Nebert DW, 1998, Nonallelism for the audiogenic seizure-prone (Asp1) and the aryl hydrocarbon receptor (Ahr) loci in mice. J Neurogenetics 12, 191-203
444. Vorhees CV, Morford LL, Inman SL, Reed TM, Schilling MA, Cappon GD, Moran MS, Nebert DW, 1999, Genetic differences in spatial learning between Dark Agouti and Sprague-Dawley strains: possible correlation with the Cyp2d2 polymorphism in rats treated neonatally with methamphetamine. Pharmacogenetics 9, 171-181
445. Carvan MJ III, Ponomareva LV, Solis WA, Matlib RS, Puga A, Nebert DW, 1999, Trout CYP1A3 gene: recognition of fish DNA motifs by mouse regulatory proteins. Marine Biotechnol 1, 155-166
446. Nebert DW, Ingelman-Sundberg M, Daly AK, 1999, Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. Drug Metab Rev 31, 467-487 PMID: 10335448
447. Dey A, Jones JE, Nebert DW, 1999, Tissue- and cell type-specific expression of cytochrome P450 1A1 and cytochrome P450 1A2 mRNA in the mouse localized by in situ hybridization. Biochem Pharmacol 58, 525-537
448. Nebert DW, 1999, Environmental susceptibility genes that cause toxicity and cancer. Proc Annu Mtg Jpn Soc Toxicol, 53-57
449. Vasiliou V, Bairoch A, Tipton KF, Nebert DW, 1999, Eukaryotic aldehyde dehydrogenase (ALDH) genes: human polymorphisms, and recommended nomenclature based on divergent evolution and chromosomal mapping. Pharmacogenetics 9, 421-434
450. Shertzer HG, Puga A, Chang CY, Smith P, Nebert DW, Setchell KDR, Dalton TP, 1999, Inhibition of CYP1A1
activity in mouse hepatoma cell culture by soybean isoflavones. Chem-Biol Interactions 123, 31-49
451. Vasiliou V, Reuter SF, Williams S, Puga A, Nebert DW, 1999, Mouse cytosolic class 3 aldehyde dehydrogenase (Aldh3a1): gene structure and regulation of constitutive and dioxin-inducible expression. Pharmacogenetics 9, 569- 580
452. Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet 1999; 56: 247-258 PMID: None
453. Nebert DW, Roe AL, Dieter MZ, Solis WA, Yang Y, Dalton TP. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem Pharmacol 2000; 59: 65-85
454. Dalton TP, Dieter MZ, Matlib RS, Childs N, Shertzer HG, Genter MB, Nebert DW. Targeted knockout in the Cyp1a1 gene does not alter hepatic constitutive expression of other genes in the mouse [Ah] battery. Biochem Biophys Res Commun 2000; 267: 184-189
455. Sinclair PR, Gorman N, Walton HS, Bement WJ, Dalton TP, Sinclair JF, Smith AG, Nebert DW. CYP1A2 is essential in mouse uroporphyria caused by hexachlorobenzene and iron. Toxicol Appl Pharmacol 2000; 162: 60-67
456. Ingelman-Sundberg M, Daly AK, Oscarson M, Nebert DW. Human cytochrome P450 (CYP) genes: recommen- dations for the nomenclature of alleles [Letter-to-the-Editor]. Pharmacogenetics 2000; 10: 91-93
457. Vasiliou V, Buetler T, Eaton DL, Nebert DW. Comparison of oxidative stress response parameters in newborn mouse liver versus SV40-transformed hepatocyte cell lines, Biochem Pharmacol 2000; 59: 703-712
458. Dalton TP, Miller ML, Wu X, Menon A, Cianciolo E, McKinnon RA, Smith PW, Robinson LJ, Nebert DW. Refining the mouse chromosomal location of Cdm, the major gene associated with susceptibility to cadmium-induced testicular necrosis. Pharmacogenetics 2000; 10: 141-151
459. Plastaras JP, Guengerich FP, Nebert DW, Marnett LJ. Xenobiotic-metabolizing cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the mutagen, malondialdehyde. J Biol Chem 2000; 275: 11784-11790
460. Carvan MJ III, Solis WA, Gedamu L, Nebert DW. Activation of transcription factors in zebrafish cell cultures by environmental pollutants. Arch Biochem Biophys 2000; 376: 320-327
461. Nebert DW. Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology. Pharmacogenetics 2000; 10: 279-290
462. Dalton TP, Solis WA, Nebert DW, Carvan MJ III. Characterization of the MTF-1 transcription factor from zebrafish and trout cells. J Compar Physiol Biochem Part B 2000; 126: 325-335
463. Carvan MJ III, Dalton TP, Stuart GW, Nebert DW. Transgenic zebrafish as a sentinel for aquatic pollution. Ann NY Acad Sci 2000; 919: 133-147
464. Nebert DW, Dalton TP, Stuart GW, Carvan MJ III. “Gene-swap knock-in” cassette in mice to study allelic differences in human genes. Ann NY Acad Sci 2000; 919: 148-170
465. Nebert DW, Dieter MZ. The evolution of drug metabolism. Pharmacology 2000; 61: 124-135
466. Nebert, DW. Drug-metabolizing enzymes, polymorphisms and interindividual response to environmental toxicants.
Clin Chem Lab Med 2000; 38: 857-861
467. Sinclair PR, Gorman N, Walton HS, Bement WJ, Szakacs J, Gonzalez FJ, Dalton TP, Nebert DW, Sinclair JF. Relative roles of CYP2E1 and CYP1A2 in mouse uroporphyria caused by acetone. Arch Biochem Biophys 2000; 384: 383-390
468. Dalton TP, Dieter MZ, Yang Y, Shertzer HG, Nebert DW. Knockout of the mouse glutamate-cysteine ligase catalytic subunit (Gclc) gene: embryonic lethal when homozygous, and proposed model for moderate glutathione deficiency when heterozygous. Biochem Biophys Res Commun 2000; 279: 324-329
469. Nebert DW. “Extreme discordant phenotype” methodology: an intuitive approach to clinical pharmacogenetics. Eur J
Pharmacol 2000; 410: 107-120 PMID: 11134663
470. Nebert DW, Roe AL. Ecogenetics: the study of gene-environment interactions. In: Patty’s Toxicology (Bingham E,
Cohrssen B, Powell C, eds), 5th Edition, Volume I, John Wiley & Sons, Inc., New York, Chapter 7, 2001; pp 1-35
471. Dieter MZ, Freshwater SL, Solis WA, Nebert DW, Dalton TP. Tyrphostin AG879, a tyrosine kinase inhibitor: prevention of transcriptional activation of the electrophile and the aromatic hydrocarbon response element. Biochem Pharmacol 2001; 61: 215-225
472. Zaccaro C, Sweitzer S, Pipino S, Gorman N, Sinclair PR, Sinclair JF, Nebert DW, de Matteis F. Role of cytochrome P450 1A2 in bilirubin degradation. Studies in Cyp1a2(-/-) mutant mice. Biochem Pharmacol 2001; 61: 843-849
473. Nebert DW, Menon AG. Pharmacogenomics, ethnicity, and susceptibility genes. Pharmacogenomics J 2001; 1: 19- 22
474. Smith AG, Clothier B, Carthew P, Childs NL, Sinclair PR, Nebert DW, Dalton TP. Protection of the Cyp1a2(-/-) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 2001; 173: 89-98
475. Shertzer HG, Nebert DW, Senft AP, Dingeldein M, Genter MB, Dalton TP. Spectrophotometric assay for acetanilide 4-hydroxylase, an estimate of CYP1A2 enzyme activity. Toxicol Methods 2001; 11: 81-88
476. Nebert DW, Roe AL. Ethnic and genetic differences in metabolism genes and risk of toxicity and cancer. Sci Total Environ 2001; 274: 93-102
477. Nebert DW, Bingham E. Pharmacogenomics: out of the lab and into the community. Trends Biotechnol 2001; 19: 519-523
478. Ingelman-Sundberg M, Oscarson M, Daly AK, Garte S, Nebert DW. Human cytochrome P450 (CYP) genes: a web page for the nomenclature of alleles [Letter-to-the-Editor]. Cancer Epidemiol Biomarkers Prev 2001; 10: 1307-1308
479. Nebert DW, Menon A. Reply to Kalow et al. letter. Pharmacogenomics J 2001; 1: 238-239
480. Dalton TP, Kerzee JK, Wang B, Miller M, Dieter MZ, Lorenz JN, Shertzer HG, Nebert DW, Puga A. Dioxin exposure
is an environmental risk factor for ischemic heart disease. Cardiovasc Toxicol 2001; 1: 285-298
481. Uno S, Dalton TP, Shertzer HG, Genter MB, Warshawsky D, Talaska G, Nebert DW. Benzo[a]pyrene-induced toxicity: paradoxical protection in Cyp1a1(–/–) knockout mice having increased hepatic BaP-DNA adduct levels. Biochem Biophys Res Commun 2001; 289: 1049-1056
482. Nebert DW, Jorge-Nebert LF. Pharmacogenetics and pharmacogenomics. In: Emery & Rimoin’s Principles and Practice of Medical Genetics (Rimoin DL, Connor JM, Pyeritz RE, Korf BR, eds), 4th ed, Churchill Livingstone, London, 2002; vol I, pp 590-631
483. Senft AP, Dalton TP, Nebert DW, Genter MB, Hutchinson RJ, Shertzer HG. Dioxin increases reactive oxygen production in mouse liver mitochondria. Toxicol Appl Pharmacol 2002; 178: 15-21
484. Nebert DW, Stuart GW, Solis WA, Carvan MJ III. Use of reporter genes and vertebrate DNA motifs in transgenic zebrafish as sentinels for assessing aquatic pollution. Environ Health Perspect 2002; 110: A15
485. Solis WA, Childs NL, Weedon MN, He L, Nebert DW, Dalton TP. Retrovirally expressed metal response element- binding transcription factor-1 normalizes metallothionein-1 gene expression and protects cells against zinc, but not cadmium, toxicity. Toxicol Appl Pharmacol 2002; 178: 93-101
486. Nebert DW, Roe AL, Vandale SL, Bingham E, Oakley GG. NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med 2002; 4: 62-70

487. Gorman N, Ross KL, Walton HS, Bement WJ, Szakacs JG, Gerhard GS, Dalton TP, Nebert DW, Eisenstein RS, Sinclair JF, Sinclair PR. Uroporphyria in mice: thresholds for hepatic CYP1A2 and iron. Hepatology 2002; 35: 912- 921
488. Solis WA, Dalton TP, Dieter MZ, Freshwater S, Harrer JM, He L, Shertzer HG, Nebert DW. Glutamate-cysteine ligase modifier subunit: mouse Gclm gene structure and regulation by agents that cause oxidative stress. Biochem Pharmacol 2002; 63: 1739-1754
489. Nebert DW. Ecogenetics: genetic susceptibility to environmental adversity. In: Biomarkers of Environmentally Associated Disease: Technologies, Concepts and Perspectives (Wilson SH, Suk WA, eds), Lewis Publishers / CRC Press, Boca Raton FL, 2002; pp 39-54
490. Shertzer HG, Dalton TP, Talaska G, Nebert DW. Decrease in 4-aminobiphenyl-induced methemoglobinemia in Cyp1a2(-/-) knockout mice. Toxicol Appl Pharmacol 2002; 181: 32-37
491. Su ZG, Zhang SZ, Hou YP, Nebert DW, Zhang L, Huang L, Liao LC, Xiao CY. Novel allele in the promoter of the hepatic lipase (LIPC) gene is associated with increased concentration of high-density-lipoprotein cholesterol and decreased promoter activity. J Lipid Res 2002; 43: 1595-1601 PMID: 12364543
492. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002; 360: 1155-1162 PMID: 12387968
493. Senft AP, Dalton TP, Nebert DW, Genter MB, Puga A, Hutchinson RJ, Kerzee JK, Uno S, Shertzer HG. Mitochondrial reactive oxygen production is dependent on the aromatic hydrocarbon receptor. Free Radic Biol Med 2002; 33: 1268-1278
494. Su ZG, Zhang SZ, Hou YP, Li T, Nebert DW, Zhang L, Huang DJ, Liao LC, Xiao CY. Single-nucleotide polymorphisms in the lipoprotein lipase (LPL) gene associated with coronary heart disease in Chinese. Eur J Pharmacol 2002; 454: 9–18 PMID: 12408999
495. Nebert DW. Proposal for an allele nomenclature system based on the evolutionary divergence of haplotypes. Hum Mutat 2002; 20: 463-472
496. Nebert DW. Transcription factors and cancer: an overview. Toxicology 2002; 181-182: 131-141
497. Yang Y, Dieter MZ, Chen Y, Shertzer HG, Nebert DW, Dalton TP. Initial characterization of the glutamate-cysteine ligase modifier subunit Gclm(–/–) knockout mouse: novel model system for a severely compromised oxidative stress response. J Biol Chem 2002; 297: 49446-49452
498. Shertzer HG, Nebert DW. A toxicological perspective on catastrophic injury: environmental arsenic. In: The Catastrophic Injury Handbook (Anchor KN, Shmerling JE, Anchor JM, eds) Kendall/Hunt Publishers, Dubuque, Iowa, 2003; Chapter 23, pp 280-288
499. Smith AG, Davies R, Dalton TP, Miller ML, Judah D, Riley J, Gant T, Nebert DW. Intrinsic hepatic phenotype associated with the Cyp1a2 gene as shown by cDNA expression microarray analysis of the knockout mouse. EHP Toxicogenomics 2003; 111: 45-51 & 855-861
500. Nichols RC, Cooper S, Trask HW, Gorman N, Dalton TP, Nebert DW, Sinclair JF, Sinclair PR. Uroporphyrin accumulation in hepatoma cells expressing human or mouse CYP1A2: relation to role of CYP1A2 in human porphyria cutanea tarda. Biochem Pharmacol 2003; 65: 545-550
501. Miller ML, Andringa A, Turner LT, Dalton TP, Derkenne S, Nebert DW. Quantitative morphometric analysis of gingival volume using dental impression materials: preservation of the negative image of enamel in decalcified histological preparations. Microsc Res Tech 2003; 60: 528-536
502. Shertzer HG, Dalton TP, Talaska G, Nebert DW. Reply to the letter by Elmar Richter. Toxicol Appl Pharmacol 2003; 188: 200-201
503. Nebert DW, Nelson DR. Cytochrome P450 (CYP) superfamily. In: Encyclopedia of the Human Genome [on the web], Nature Publishing Group, London, 2003; article #667
504. Nebert DW. Pharmacogenetics and pharmacogenomics. In: Encyclopedia of the Human Genome [on the web],
Nature Publishing Group, London, 2003; article #A558
505. Nebert DW. Evolution of drug metabolism. In: Encyclopedia of the Human Genome [on the web], Nature
Publishing Group, London, 2003; article #A1143
506. Dieter MZ, Freshwater SL, Miller ML, Shertzer HG, Dalton TP, Nebert DW. Pharmacological rescue of the 14CoS/14CoS mouse: hepatocyte apoptosis is likely caused by endogenous oxidative stress. Free Radic Biol Med 2003; 35: 351-367
507. Tsuneoka Y, Dalton TP, Miller ML, Clay CD, Shertzer HG, Talaska G, Medvedovic M, Nebert DW. 4-Amino- biphenyl-induced liver and urinary bladder DNA adduct formation in Cyp1a2(-/-) and Cyp1a2(+/+) mice. J Natl Cancer Inst 2003; 95: 1227-1237
508. Nebert DW, Wain HM. Update on human genome completion and annotations: gene nomenclature. Hum Genomics 2003; 1: 66-71
509. Nebert DW, Jorge-Nebert LF, Vesell ES. Pharmacogenomics and “individualized drug therapy”: high expectations and disappointing achievements. Am J Pharmacogenomics 2003; 3: 361–370 PMID: 14672516
510. Uno S, Wang B, Shertzer HG, Nebert DW, Dalton TP. Balancer-Cre transgenic mouse germ cells direct the incomplete resolution of a tri-loxP-targeted Cyp1a1 allele, producing a conditional knockout allele. Biochem Biophys Res Commun 2003; 312: 494-499
511. Nelson DR, Zeldin D, Hoffman S, Maltais L, Wain HM, Nebert DW. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes including nomenclature recommendations for genes, pseudogenes, and alternative-splice variants. Pharmacogenetics 2004; 14: 1-18
512. Nelson DR, Nebert DW. The truth about mouse, human, worms and yeast. Hum Genomics 2004; 1: 146-149
513. Toraason M, Albertini R, Bayard S, Bigbee W, Blair A, Boffetta P, Bonassi S, Chanock S, Christiani D, Eastmond D, Hanash S, Henry C, Kadlubar FF, Mirer F, Nebert DW, Rapport S, Rest K, Rothman N, Ruder A, Savage R, Schulte P, Siemiatycki J, Shields P, Smith M, Tolbert P, Vermeulen R, Vineis P, Wacholder S, Ward E, Waters M, Weston A. Applying new biotechnologies to the study of occupational cancer–a workshop summary. Toxicogenomics 2004; 112: 413-416
514. Shertzer HG, Clay CD, Genter MB, Schneider SN, Nebert DW, Dalton TP. CYP1A2 protects against reactive oxygen production in mouse liver microsomes. Free Radic Biol Med 2004; 36: 605-617
515. Shertzer HG, Clay CD, Genter MB, Chames MC, Schneider SN, Oakley GG, Nebert DW, Dalton TP. Uncoupling- mediated generation of reactive oxygen by halogenated aromatic hydrocarbons in mouse liver microsomes. Free Radic Biol Med 2004; 36: 618-631
516. Wu C, Nebert DW. Update on gene completions and annotations: Protein Information Resource. Hum Genomics 2004; 1: 229-233
517. Uno S, Dalton TP, Sinclair PR, Gorman N, Wang B, Smith AG, Miller ML, Shertzer HG, Nebert DW. Cyp1a1(-/-) male mice: protection against high-dose TCDD-induced lethality and wasting syndrome, and resistance to intra- hepatocyte lipid accumulation and uroporphyria. Toxicol Appl Pharmacol 2004; 196: 410-421
518. Uno S, Dalton TP, Derkenne S, Curran CP, Miller ML, Shertzer HG, Nebert DW. Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. Mol Pharmacol 2004; 65: 1225-1237
519. Zhang K, Zhang S, Zheng K, Hou Y, Liao L, He Y, Zhang L, Nebert DW, Shi J, Su Z, Qiu W, Xiao C. Novel P143L polymorphism of the LCAT gene is associated with dyslipidemia in Chinese patients who have coronary atherosclerotic heart disease. Biochem Biophys Res Commun 2004; 318: 4–10 PMID: 15110745
520. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 2004; 279: 23847–23850
521. Nebert DW, Sophos NA, Vasiliou V, Nelson DR. Cyclophilin nomenclature problems, or, “A visit from the sequence
police.” Hum Genomics 2004; 1: 381–388
522. Mashek DG,Bornfeldt KE, Coleman RA, Berger J, Bernlohr DA, Black P, DiRusso CC, Farber SA, Guo W, Hashimoto N, Khodiyar V, Kuypers FA, Maltais LJ, Nebert DW, Renieri A, Schaffer JE, Stahl A, Watkins PA, Vasiliou V, Yamamoto TT. Revised nomenclature for the mammalian long-chain acyl-CoA synthetase gene family. J Lipid Res 2004; 45: 1958–1961
523. Nebert DW, Vesell ES. Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. Eur J Pharmacol 2004; 500: 267–280 PMID: 15464039
524. Dalton TP, Chen Y, Schneider SN, Nebert DW, Shertzer HG. Genetically altered mice to evaluate glutathione homeostasis in health and disease. Free Radic Biol Med 2004; 37: 1511–1526
525. Kleiner HE, Vulimiri SV, Hatten WB, Reed MJ, Nebert DW, Jefcoate CR, DiGiovanni J. Role of CYP1 family members in the metabolic activation of polycyclic aromatic hydrocarbons in mouse epidermis. Chem Res Toxicol 2004; 17: 1667-1674
526. Nebert DW, Vasiliou V. Analysis of the glutathione S-transferase (GST) gene family. Hum Genomics 2004; 1: 460- 464
527. Nebert DW. Conflicts of interest: declarations for all. Environ Health Perspect 2004; 112: A980
528. Nebert DW. The scientific career of Daniel W Nebert. Proceedings of the 15th International Symposium on
Microsomes and Drug Oxidations (Oesch F, ed) Medimond S.R.L. Publishers, Bologna, Italy, 2004; pp 25-32
529. Jiang ZW, Dalton TP, Jin L, Wang B, Tsuneoka Y, Shertzer HG, Deka R, Nebert DW. Toward the evaluation of function in genetic variability: characterizing human SNPs and establishing BAC-transgenic mice carrying the human CYP1A1_CYP1A2 locus. Hum Mutat 2005; 25: 196–206 PMID: 15643613
530. Dalton TP, He L, Wang B, Miller ML, Jin L, Stringer KF, Chang XQ, Baxter GS, Nebert DW. Identification of mouse SLC39A8 as the transporter responsible for cadmium-induced toxicity in the testis. Proc Natl Acad Sci USA 2005; 102: 3401-3406
531. Greaves P, Clothier B, Davies R, Higginson FM, Edwards RE, Dalton TP, Nebert DW, Smith AG. Uroporphyria and hepatic carcinogenesis induced by polychlorinated biphenyls-iron interaction: absence in the Cyp1a2(-/-) knockout mouse. Biochem Biophys Res Commun 2005; 331: 147-152
532. Vasiliou V, Nebert DW. Analysis and update of the human aldehyde dehydrogenase (ALDH) gene superfamily. Hum Genomics 2005; 2: 138-143
533. LiuH,ZhangS,LinJ,LiH,HuangA,XiaoC,LiC,SuZ,WangC,NebertDW,ZhouB,ZhengK,ShiJ,LiG, Huang D. Association between DNA variant sites in the apolipoprotein-A5 gene and coronary heart disease in Chinese. Metabolism 2005; 54: 568-572 PMID: 15877284
534. Derkenne S, Curran CP, Shertzer HG, Dalton TP, Dragin N, Nebert DW. Theophylline pharmacokinetics: comparison of Cyp1a1(-/-) and Cyp1a2(-/-) knockout mice, humanized hCYP1A1_1A2 knock-in mice lacking either the mouse Cyp1a1 or Cyp1a2 gene, and Cyp1(+/+) wild-type mice. Pharmacogenet Genomics 2005; 15: 503-511
535. Nebert DW. Role of host susceptibility to toxicity and cancer caused by pesticides: cytochromes P450. J Biochem Mol Toxicol 2005; 19: 184-186
536. Shen D, Dalton TP, Nebert DW, Shertzer HG. Glutathione redox state regulates mitochondrial reactive oxygen production. J Biol Chem 2005; 280: 25305-25312
537. Cheung C, Ma X, Krausz KW, Kimura S, Feigenbaum L, Dalton TP, Nebert DW, Idle JR, Gonzalez FJ. Differential metabolism of 2-amino-1-methyl-6-phenylimidazol[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2. Chem Res Toxicol 2005; 17: 1667-1674
538. Nebert DW. Interindividual susceptibility to environmental toxicants—a current assessment. Toxicol Appl Pharmacol 2005; 207: 34-42

539. Mackenzie PI, Bock WK, Burchell B, Guillemette C, Ikushiro SI, Iyanagi T, Miners JO, Owens IS, Nebert DW. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 2005; 15: 677-685
540. Chen Y, Shertzer HG, Schneider SN, Nebert DW, Dalton TP. Glutamate-cysteine ligase catalysis: dependence on ATP and GCLM for regulation of tissue glutathione levels. J Biol Chem 2005; 280: 33766-33774
541. Nebert DW. Editorial Focus. Comparison of gene expression in cell culture with that in the intact animal: relevance to drugs and environmental toxicants. Am J Physiol–Cell Physiol 2006; 290: C37-C41
542. Curran CP, Miller KA, Dalton TP, Vorhees CV, Miller ML, Shertzer HG, Nebert DW. Genetic differences in lethality of newborn mice treated in utero with coplanar versus non-coplanar hexabromobiphenyl. Toxicol Sci 2006; 89: 454– 464
543. LiY,ZhangD,JinW,ShaoC,YanP,XuC,ShengH,LiuY,YuJ,XieY,ZhaoY,LuD,NebertDW,HarrisonDC, Huang W, Jin L. Mitochondrial aldehyde dehydrogenase-2 (ALDH2) Glu504Lys polymorphism contributes to the variation in efficacy of sublingual nitroglycerin. J Clin Invest 2006; 116: 506–511 PMID: 16440063
544. Genter MB, Clay CD, Dalton TP, Dong H, Nebert DW, Shertzer HG. Comparison of mouse hepatic mitochondrial versus microsomal cytochromes P450 following dioxin treatment. Biochem Biophys Res Commun 2006; 342: 1375- 1381
545. Vasiliou V, Ross D, Nebert DW. Update of the NAD(P)H:quinone oxidoreductase (NQO) gene family. Hum Genomics 2006; 2: 329-335
546. Uno S, Dalton TP, Dragin N, Curran CP, Derkenne S, Miller ML, Shertzer HG, Gonzalez FJ, Nebert DW. Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate. Mol Pharmacol 2006; 69: 1103–1114
547. Jiang ZW, Dragin N, Jorge-Nebert LF, Martin MV, Guengerich FP, Aklillu E, Ingelman-Sundberg M, Hammons GJ, Lyn-Cook BD, Kadlubar FF, Saldaña SN, Sorter M, Vinks AA, Nassr N, von Richter O, Jin L, Nebert DW. Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet Genomics 2006; 16: 359–367 PMID: 16609368
548. Zhang G, Nebert DW, Chakraborty R, Jin L. Statistical power of association using the extreme discordant phenotype design. Pharmacogenet Genomics 2006; 16: 401–413 PMID: 16708049
549. Dragin N, Dalton TP, Miller ML, Shertzer HG, Nebert DW. Dioxin-induced birth defects: mouse or human CYP1A2 in maternal liver protects, whereas mouse CYP1A1 and CYP1B1 are inconsequential. J Biol Chem 2006; 281: 18591- 18600
550. He L, Girijashanker K, Dalton TP, Reed J, Li H, Soleimani M, Nebert DW. ZIP8, member of the solute-carrier-39 (SLC39) metal transporter family: characterization of transporter properties. Mol Pharmacol 2006; 70: 171-180
551. Genter MB, Marlowe J, Kerzee JK, Dragin N, Puga A, Dalton TP, Nebert DW. Naphthalene toxicity in mice and aryl hydrocarbon receptor-mediated CYPs. Biochem Biophys Res Commun 2006; 348: 120-123
552. Ingelman-Sundberg M, Sim SC, Nebert DW. Coffee, myocardial infarction, and CYP gene nomenclature. J Am Med Assn 2006; 296: 764-765
553. Dasari VR, Anandatheerthavarada HK, Robin MA, Boopathi E, Biswas G, Fang JK, Nebert DW, Avadhani NG. Role of protein kinase C-mediated protein phosphorylation in mitochondrial translocation of CYP1A1, which contains a non-canonical targeting signal. J Biol Chem 2006; 281: 30834-30847
554. Nebert DW, Vesell ES. Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics. Trends Pharmacol Sci 2006; 27: 580–586 PMID: 17005258
555. Nebert DW, Dalton TP. Role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 2006; 6: 947-960
556. Goldstone JV, Hamdoun A, Cole BJ, Howard-Ashby M, Nebert DW, Scally M, Dean M, Epel D, Hahn ME, Stegeman JJ. The chemical defensome: environmental sensing and response genes in the Strongylocentrotus purpuratus genome. Dev Biol 2006; 300: 366-384
557. Shertzer HG, Genter MB, Shen D, Nebert DW, Chen Y, Dalton TP. TCDD decreases ATP levels and increases reactive oxygen production through changes in mitochondrial F0/F1-ATP synthase and ubiquinone. Toxicol Appl Pharmacol 2006; 217: 363-374
558. Nebert DW, Jorge-Nebert LF. Pharmacogenetics and pharmacogenomics. In: Emery & Rimoin’s Principles and Practice of Medical Genetics (Rimoin DL, Connor JM, Pyeritz RE, Korf BR, eds), 5th ed, Churchill Livingstone, London, 2007; vol. I, Section I, Chapter 23, pp 456–498
559. Jorge-Nebert LF, Derkenne S, Nebert DW. Drugs and the mouse: pharmacology, pharmacogenetics, and pharmaco- genomics. In: The Mouse in Biomedical Research , 2nd ed, (Fox JG, Barthold SW, Davisson MT, Newcomer CE, Quimby FW, Smith AL, eds), Elsevier Press, San Diego, CA, 2007; vol I, Chapter 16, pp 289–320
560. Ma X, Idle JR, Malfatti M, Krausz KW, Nebert DW, Chen CS, Felton JS, Waxman DJ, Gonzalez FJ. Mouse lung CYP1A1 catalyzes the metabolic activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Carcino- genesis 2007; 28: 732–737
561. Wang B, Schneider SN, Dragin N, Girijashanker K, Dalton TP, He L, Miller ML, Stringer KF, Soleimani M, Richardson DD, Nebert DW. Enhanced cadmium-induced testicular necrosis and renal proximal tubule damage caused by gene-dose increase in a Slc39a8-transgenic mouse line. Am J Physiol Cell Physiol 2007; 292: C1523-C1535
562. Chen Y, Yang Y, Miller ML, Shen D, Shertzer HG, Stringer KF, Wang B, Schneider SN, Nebert DW, Dalton TP. Hepatocyte-specific Gclc deletion leads to rapid onset of steatosis with mitochondrial injury and liver failure. Hepatology 2007; 45: 1118–1128
563. Shertzer HG, Genter MB, Talaska G, Curran CP, Nebert DW, Dalton TP. 7H-Dibenzo[c,g]carbazole metabolism by the mouse and human CYP1 family of enzymes. Carcinogenesis 2007; 28: 1371–1378
564. Yang Y, Chen Y, Johansson E, Schneider SN, Shertzer HG, Nebert DW, Dalton TP. Interaction between the catalytic and modifier subunits of glutamate-cysteine ligase. Biochem Pharmacol 2007; 74: 372–381
565. Dragin N, Uno S, Wang B, Dalton TP, Nebert DW. Generation of ‘humanized’ hCYP1A1_1A2_Cyp1a1/1a2(-/-) mouse line. Biochem Biophys Res Commun 2007; 359: 635–642
566. Cotton RGH, Auerbach AD, Brown AF, Carrera P, Christodoulou J, Claustres M, Compton J, Cox JD, De Baere E, den Dunnen JT, Greenblatt M, Fujiwara M, Hilbert P, Jani A, Lehvaslaiho H, Nebert DW, Verma I, Vihinen M: The Human Variome Project Diagnostic Laboratory Working Group. A structured simple form for ordering genetic tests is needed to ensure coupling clinical detail (phenotype) with DNA vaariants (genotype) to guarantee utility in publication and databases. Hum Mutat 2007; 28: 931–932
567. Nebert DW. CYP1A2 from a disease perspective. PGBase [leading resource for the pharmacogenomics and persona- lized medicine community], 2007; published online by Future Biology Ltd, London, United Kingdom
568. Cotton RG, Auerbach AD, Beckmann JS, Blumenfeld OO, Brookes AJ, Brown AF, Carrera P, Cox DW, Gottlieb B, Greenblatt MS, Hilbert P, Lahvaslaiho H, Liang P, Marsh S, Nebert DW, Povey S, Rossetti S, Scriver CR, Summar M, Tolan DR, Verma IC, Vihinen M, den Dunnen JT. Recommendations for locus-specific databases and their curation. Hum Mutat 2008; 29: 2–5
569. Liu ZW, Li–H, Soleimani M, Girijashanker K, Reed JM, He L, Dalton TP, Nebert DW. Cd2+ or Zn2+ uptake by the ZIP8 HCO3 -dependent symporter: kinetics, electrogenicity and trafficking. Biochem Biophys Res Commun, 2008; 365: 814–820
570. Uno S, Dragin N, Miller ML, Dalton TP, Gonzalez FJ, Nebert DW. Basal and inducible CYP1 mRNA quantitation and protein localization throughout mouse gastrointestinal tract. Free Rad Biol Med 2008; 44: 570–583
571. Prozialeck WC, Edwards JR, Nebert DW, Woods JM, Barchowsky A, Atchison WD. The vascular system as a target of metal toxicity. Toxicol Sci 2008; 102: 207–218
572. Bernstein JA, Zhang G, Jin L, Abbot C, Nebert DW. Olfactory receptor gene polymorphisms and nonallergic
vasomotor rhinitis. J Asthma 2008; 45: 1–6 PMID: 18446592
573. Nebert DW. Pharmacogenetics and pharmacogenomics. In: Encyclopedia of the Life Sciences [on the web], John Wiley & Sons, Ltd., Chichester, United Kingdom, April 2008; http://www.els.net/
[DOI: 10.1002/9780470015902.a0005558.pub2]
574. Girijashanker K, He L, Liu ZW, Reed JM, Li H, Soleimani M, Dong HB, Dalton TP, Nebert DW. Slc39a8 gene product: ZIP14 is metal/bicarbonate symporter, like ZIP8. Mol Pharmacol 2008; 73: 1413–1423
575. Nebert DW, Zhang G, Vesell ES. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev 2008; 40: 1–38 PMID: 18464043
576. Dragin N, Shi ZQ, Madan R, Karp CL, Sartor MA, Chen C, Gonzalez FJ, Nebert DW. Phenotype of the Cyp1a1/1a2/1b1(–/–) triple-knockout mouse. Mol Pharmacol 2008; 73: 1844–1856
577. Olender T, Lancet D, Nebert DW. Update on the olfactory gene (OR) superfamily. Hum Genomics 2008; 3: 87–97
578. Shi Z, Chen Y, Dong H, Amos-Kroohs RM, Nebert DW. Generation of ‘humanized’ hCYP1A1_1A2_Cyp1a1/1a2(-/-)
mouse line harboring the poor-affinity aryl hydrocarbon receptor. Biochem Biophys Res Commun 2008; 376: 775–780
579. Ma C, Schneider SN, Miller ML, Nebert DW, Lind C, Roda SM, Afteron SE, Caruso JA, Genter MB. Manganese
accumulation in the mouse ear following systemic exposure. J Biochem Mol Toxicol 2008; 22: 305–310
580. Nebert DW, Karp CL. Endogenous functions of the aryl hydrocarbon receptor (AHR): intersection of cytochrome
P450 1 (CYP1)-metabolized eicosanoids and AHR biology. J Biol Chem 2008; 283: 36061–36065
581. He L, Vasiliou K, Nebert DW. Analysis and update of the human solute-carrier (SLC) gene superfamily. Hum
Genomics 2009; 3: 195–206
582. Dong H, Dalton TP, Miller ML, Chen Y, Uno S, Shi Z, Shertzer HG, Bansal S, Avadhani NG, Nebert DW. Knock-in mouse lines expressing either mitochondrial or microsomal CYP1A1: Differing responses to dietary benzo[a]pyrene as proof-of-principle. Mol Pharmacol 2009; 75: 555–567
583. Uno S, Endo K, Ishida Y, Tateno C, Makishima M, Yoshizato K, Nebert DW. CYP1A1 and CYP1A2 expression: comparing ‘humanized’ mouse lines and wild-type mice; comparing human and mouse hepatoma-derived cell lines. Toxicol Appl Pharmacol 2009; 237: 119–126
584. Sim SC, Miller WL, Zhong XB, Arlt W, Ogata T, Ding X, Wolf CR, Fluck CE, Pandey AV, Henderson CJ, Porter TD, Daly AK, Nebert DW, Ingelman-Sundberg M. Nomenclature for alleles of the cytochrome P450-oxidoreductase (POR) gene. Pharmacogenet Genomics 2009; 19: 565–566
585. Nebert DW, Vasiliou K. Update on gene completions and annotations: Human ATP-binding cassette (ABC) transporter family. Hum Genomics 2009; 3: 281–290
586. He L, Wang B, Hay EB, Nebert DW. Discovery of ZIP transporters that participate in cadmium damage to testis and kidney. Toxicol Appl Pharmacol 2009; 238: 250–257
587. Chen Y, Johansson E, Fan Y, Shertzer HG, Vasiliou V, Nebert DW, Dalton TP. Early-onset senescence occurs when fibroblasts lack the glutamate-cysteine ligase modifier subunit. Free Rad Biol Med 2009; 47: 410–418
588. Nebert DW. Given the complexity of the human genome, can ‘personalised medicine’ or ‘individualised drug therapy’ ever be achieved? Hum Genomics 2009; 3: 299–300
589. Black WJ, Stagos D, Marchitti SA, Nebert DW, Tipton KF, Bairoch A, Vasiliou V. Mammalian aldehyde dehydrogenase genes: alternatively-spliced transcriptional variants and their suggested nomenclature. Pharmacogenet Genomics 2009; 19: 893–902
590. Brocker CN, Vasiliou V, Nebert DW. Evolutionary divergence and functions of the ADAM and ADAMTS gene families. Hum Genomics 2009; 4: 43–55

591. Jorge-Nebert LF, Jiang ZW, Chakraborty R, Watson J, Jin L, McGarvey ST, Deka R, Nebert DW. Analysis of human CYP1A1 and CYP1A2 genes and their shared bidirectional promoter in eight world populations. Hum Mutat 2010; 31: 27–40 PMID: 19802894
592. Fan Y, Boivin GP, Knudsen ES, Nebert DW, Xia Y, Puga A. The aryl hydrocarbon receptor functions as a tumor suppressor in liver carcinogenesis. Cancer Res 2010; 70: 212–220
593. Jackson BC, Nebert DW, Vasiliou V. Update of human and mouse matrix metalloproteinase families. Hum Genomics 2010; 4: 194–201
594. Shi Z, Dragin N, Gálvez-Peralta M, Jorge-Nebert LF, Miller ML, Wang B, Nebert DW. Organ-specific roles of CYP1A1 during detoxication of oral benzo[a]pyrene. Mol Pharmacol 2010; 78: 46–57
595. Shi Z, Dragin N, Miller ML, Stringer KF, Johansson E, Chen J, Uno S, Gonzalez FJ, Rubio C, Nebert DW. Oral benzo[a]pyrene-induced cancer: two distinct types in different target organs dependent on the mouse Cyp1 genotype. Intl J Cancer 2010; 127: 2334–2350
596. Jackson BC, Carpenter C, Nebert DW, Vasiliou V. Update of human and mouse forkhead (FOX) gene families. Hum Genomics 2010; 4: 345–352
597. Brocker C, Carpenter C, Nebert DW, Vasiliou V. Evolutionary divergence and functions of the human acyl-CoA thioesterase gene (ACOT) family. Hum Genomics 2010; 4: 411-420
598. Nebert DW, Gálvez-Peralta M, Shi Z, Dragin N. Inbreeding and epigenetics: beneficial as well as deleterious effects. Nat Rev Genet 2010; 11: 662
599. Brocker C, Thompson D, Matsumoto A, Nebert DW, Vasiliou V. Evolutionary divergence and functions of the human interleukin gene (IL) family. Hum Genomics 2010; 5: 30–55
600. Chen Y, Johansson E, Yang Y, Miller ML, Shen D, Orlicky DJ, Shertzer HG, Vasiliou V, Nebert DW, Dalton TP. Oral N-acetylcysteine rescues lethality of hepatocyte-specific Gclc knockout mice, providing a model for hepatic cirrhosis. J Hepatology 2010; 53: 1085–1094
601. Nelson DR, Nebert DW Cytochrome P450 (CYP) Gene Superfamily. In: Encyclopedia of Life Sciences (ELS). John Wiley & Sons, Ltd: Chichester, England, DOI: 10.1002/9780470015902.a0005667.pub2 (January 2011)
602. Ozeki J, Uno S, Ogura M, Choi M, Maeda T, Sakurai K, Matsuo S, Amano S, Nebert DW, Makishima M. Aryl hydrocarbon receptor ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin enhances liver damage in bile duct-ligated mice. Toxicology 2011; 280: 10–17
603. Curran CP, Vorhees CV, Williams MT, Genter MB, Miller ML, Nebert DW. In utero and lactational exposure to a complex mixture of polychlorinated biphenyls: toxicity in pups dependent on the Cyp1a2 and Ahr genotypes. Toxicol Sci 2011; 119: 189–208
604. Wang B, He L, Dong H, Dalton TP, Nebert DW. Generation of a Slc39a8 hypomorph mouse: markedly decreased ZIP8 Zn2+/(HCO3–)2 transporter expression. Biochem Biophys Res Commun 2011; 410: 289–294
605. Jackson BC, Brocker C, Thompson DC, Black W, Vasiliou K, Nebert DW, Vasiliou V. Update on the aldehyde dehydrogenase gene (ALDH) superfamily. Hum Genomics 2011; 5: 283–303
606. Curran CP, Nebert DW, Genter MB, Patel KV, Schafer TL, Skelton MR, Williams MT, Vorhees CV. In utero and lactational exposure to PCBs in mice: adult offspring show altered learning and memory depending on Cyp1a2 and Ahr genotypes. Environ Health Perspect 2011; 119: 1286–1293
607. Waits ER, Nebert DW. Genetic architecture of susceptibility to PCB126-induced developmental cardiotoxicity in zebrafish. Toxicol Sci 2011; 122: 466–475
608. Arlt VM, Levová K, Bárta F, Shi Z, Frei E, Schmeiser HH, Nebert DW, Phillips DH, Stiborová M. Role of P450 1A1 and P450 1A2 in bioactivation and detoxication of the renal carcinogen aristolochic acid I: studies in Cyp1a1(–/–), Cyp1a2(–/–) and Cyp1a1/1a2(–/–) mice. Chem Res Toxicol 2011; 24: 1710–1719
609. Kendig EL, Chen Y, Krishan M, Johansson E, Schneider SN, Genter MB, Nebert DW, Shertzer HG. Lipid
metabolism and body composition in Gclm(–/–) mice. Toxicol Appl Pharmacol 2011; 257: 338–348
610. Jackson BC, Thompson DC, Wright MW, McAndrews M, Emes R, Klug J, Kimura K, Nebert DW, Vasiliou V. Update of the human secretoglobin (SCGB) gene superfamily and example of an "evolutionary bloom" of androgen- binding protein genes within the mouse Scgb gene superfamily. Hum Genomics 2011; 5: 691–702
611. Chen Y, Krishan M, Nebert DW, Shertzer HG. Glutathione-deficient mice are susceptible to TCDD-induced hepatocellular toxicity, but resistant to steatosis. Chem Res Toxicol 2012; 25: 94–100
612. Stiborová M, Levová K, Bárta F, Shi Z, Frei E, Schmeiser HH, Nebert DW, Phillips DH, Arlt VM. Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2. Toxicol Sci 2012; 125: 345–358
613. Chen Y, Curran CP, Nebert DW, Patel KV, Williams MT, Vorhees CV. Effect of vitamin C deficiency during postnatal development on adult behavior: functional phenotype of Gulo(–/–) knockout mice. Genes Brain Behav 2012; 11: 269–277
614. Gálvez-Peralta M, He L, Jorge-Nebert LF, Wang B, Miller ML, Eppert BL, Afton S, Nebert DW. ZIP8 zinc transporter: indispensable role for both multiple-organ organogenesis and hematopoiesis in utero. PLoS ONE 2012; 7: e36055
615. Chen Y, Curran CP, Nebert DW, Patel KV, Williams MT, Vorhees CV. Effect of chronic glutathione deficiency on the behavioral phenotype of Gclm(–/–) knockout mice. Neurotoxicol Teratol 2012; 34: 450–457
616. Nebert DW, Zhang G. Personalized medicine: let's temper expectations. Science 2012; 337: 910
617. Nebert DW, Hay EB, Gálvez-Peralta M, Li H, Johansson E, Yin C, Wang B, He L, Soleimani M. ZIP14 and ZIP8 zinc/bicarbonate symporters: characterization in Xenopus oocytes of metal uptake and inhibition. Metallomics 2012; 4: 1218–1225
618. Levová K, Moserova M, Nebert DW, Phillips DH, Frei E, Schmeiser HH, Arlt VM, Stiborová M. NAD(P)H:quinone oxidoreductase expression in Cyp1a-knockout and CYP1A-humanized mouse lines: effects on bioactivation of the carcinogen aristolochic acid I. Toxicol Appl Pharmacol 2012; 265: 360–367
619. Fullenkamp AN, Haynes EN, Meloncon L, Succop P, Nebert DW. Perceptions of genetic research in three rural Appalachian Ohio communities. J Community Genet 2013; 4: 9–17
620. Fullenkamp AN, Haynes EN, Succop P, Nebert DW, Meloncon L. Erratum to: Perceptions of genetic research in three rural Appalachian Ohio communities. J Community Genet 2012; 4: 19
621. Brocker C, Vasiliou M, Carpenter S, Carpenter C, Zhang Y, Wang X, Kotchoni SO, Wood AJ, Kirch H-H, Kopecˇny' D, Nebert DW, Vasiliou V. Aldehyde dehydrogenase (ALDH) superfamily in plants: gene nomenclature and comparative genomics. Planta, 2013; 237: 189–210
622. Nebert DW, Wikvall K, Miller WL. Human cytochromes P450 in health and disease. Philos Trans R Soc Lond B Biol Sci 2013; 368: 20120431 (http://dx.doi.org/10.1098/rstb.2012.0431)
623. Nebert DW, Zhang G, Vesell ES. Genetic risk prediction: individualized variability in susceptibility to toxicants. Annu Rev Pharmacol Toxicol 2013; 53: 355–375
624. Nebert DW, Vesell ES. Pharmacogenetics and pharmacogenomics. In: Emery & Rimoin’s Principles and Practice of Medical Genetics (Rimoin DL, Pyeritz RE, Korf BR, eds), 6th ed, Churchill Livingstone, London, 2013; Chapter 19, 1–27 (ISBN: 9780123838346)
625. Liu MJ, Bao S, Gálvez-Peralta M, Pyle CJ, Rudawsky AC, Pavlovicz RE, Killilea DW, Li C, Nebert DW, Wewers MD, Knoell DL. ZIP8 regulates host defense through zinc-mediated inhibition of NF-κB. Cell Reports 2013; 3: 386– 400

626. Gálvez-Peralta M, Shi Z, Chen J, Miller ML, Nebert DW. Oral benzo[a]pyrene in Cyp1a1/1b1(–/–) double-knockout mouse: microarray analysis during squamous cell tumorigenesis in preputial gland duct. Intl J Cancer 2013; 132: 2065–2075
627. Dong H, Shertzer HG, Jorge-Nebert LF, Genter MG, Gonzalez FJ, Vasiliou V, Jefcoate C, Nebert DW. Mitochondrial targeting of mouse NQO1 and CYP1B1 proteins. Biochem Biophys Res Commun 2013; 435: 727–732
628. Iqbal J, Sun L, Cao J, Yuen T, Lu P, Bab I, Leu NA, Srinivasan S, Wagage S, Hunter C, Nebert DW, Zaidi M, Avadhani NG. Smoke carcinogens cause bone loss through the aryl hydrocarbon receptor and induction of CYP1 enzymes. Proc Natl Acad Sci USA 2013; 110: 11115–11120
629. Chen Y, Dong H, Thompson DC, Shertzer HG, Nebert DW, Vasiliou V. Glutathione defense mechanism in liver injury: insights from animal models. Food Chem Toxicol 2013; 60C: 38–44
630. Nebert DW, Shi Z, Gálvez-Peralta M, Uno S, Dragin N. Oral benzo[a]pyrene: understanding pharmacokinetics, detoxication and consequences––Cyp1 knockout mouse lines as a paradigm. Mol Pharmacol 2013; 84: 304–313
631. Divanovic S, Dalli J, Jorge-Nebert LF, Flick LM, Gálvez-Peralta M, Boespflug ND, Stankiewicz TE, Fitzgerald JM, Somarathna M, Karp CL, Serhan CN, Nebert DW. Contributions of the three CYP1 monooxygenases to pro- inflammatory eicosanoid and inflammation-resolution lipid-mediator pathways. J Immunol 2013; 191: 3347–3357
632. Heit C, Jackson BC, McAndrews M, Wright MW, Thompson DC, Silverman GA, Nebert DW, Vasiliou V. Update of the human and mouse SERPIN gene superfamily. Hum Genomics 2013; 7: 22
633. Schneider SN, Liu Z, Wang B, Miller ML, Afton S, Soleimani M, Nebert DW. Oral cadmium in mice carrying five, versus two, copies of Slc39a8 gene: comparison of uptake, distribution, metal content, and toxicity. Intl J Toxicol 2014; 33: 14–20
634. Uno S, Sakurai K, Nebert DW, Makishima M. Protective role of cytochrome P450 1A1 (CYP1A1) against benzo[a]pyrene-induced toxicity in mouse aorta. Toxicology 2014; 316: 34–42
635. Gálvez-Peralta M, Wang Z, Bao S, Knoell DL, Nebert DW. Mouse ZIP8 and ZIP14 divalent cation/bicarbonate symporters: tissue-specific innate response to inflammatory stimuli. Intl J Toxicol 2014; 33: 246–258
636. Jiang W, Lingappan K, Wang L, Wang G, Courouclia XI, Shivanna B, Welty SE , Barrios R, Khanc MF, Nebert DW, Roberts J, Moorthy B. Cyp1a1(–/–) knockout mice are more susceptible than wild-type to hyperoxic lung injury: Evidence for protective role of CYP1A1 against oxidative stress. Toxicol Sci 2014; 141: 68–77
637. Monte AA, Brocker C, Nebert DW, Gonzalez FJ, Thompson DC, Vasiliou V. Triangulating phenomics with genomics and metabolomics to improve drug therapy. Hum Genomics 2014 Sep 1; 8(1):16. [Epub ahead of print]
638. Jorge-Nebert LF, Gálvez-Peralta M, Landero Figueroa J, Somarathna M, Fukada T, Hirano T, Nebert DW. Comparison of oral cadmium uptake and distribution in Slc39a14(–/–) (ZIP14) knockout versus wild-type mice. Toxicol Sci 2014 Oct 7; pii: kfu204. [Epub ahead of print]
639. Nebert DW. Darwin's ideas: supported by science. Hektoen International Winter issue, 2015
640. McDermott J, Geng X, Kim J, Jiang L, Gálvez-Peralta M, Nebert DW, Liu Z. ZIP8 is an essential micronutrient
cotransporter that mediates zinc-stimulated selenite uptake. PLoS Biol 2015; under revision
641. Aronow BJ, Gálvez-Peralta M, Deng J, Nebert DW. Transcriptome analysis of Slc39a8(+/+) wild-type versus Slc39a8(neo/neo) in fetal mouse liver, lung, kidney, cerebellum, heart, yolk sac and placenta. 2014; submitted

Copyright Information © University of Cincinnati, 2012
160 Panzeca Way, Kettering Laboratory, Cincinnati, Ohio 45267-0056
Phone: (513) 558-5439 | Fax: (513) 558-4397 | E-Mail Us